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Abstract 
Breast cancer is the most common cancer in women and the leading cause of female cancer 
mortality. Family history of the disease is one of the major risk factors for breast cancer, and 
the hereditary factors also play a role in breast cancer survival. Investigation of the inherited 
variants for breast cancer risk, tumor phenotype, and prognosis can be beneficial for further 
improvements of clinical management of breast cancer patients. Recognition of patient groups 
with poor prognosis remains one of the major challenges in cancer research. 
The aim of this work was (I) to study the association of the PALB2 1592delT Finnish founder 
mutation with breast cancer risk, and together with BRCA1 and BRCA2 mutations on tumor 
phenotype and patient survival; (II) to investigate the role of germline PTEN promoter 
variation on breast cancer risk, tumor phenotype and patient survival, and (III) to evaluate the 
association of eIF4E protein expression with characteristics of breast tumors as well as on 
patient survival and treatment outcome. The germline variants were studied in a set of DNA 
samples from 1,870 unselected and 542 additional familial breast cancer patients with detailed 
information on tumor characteristics and patient survival, and from 1,079 population controls. 
The eIF4E protein expression was studied on tissue microarrays with 1,423 breast tumors. 
RNA expression analysis using gene expression microarrays was carried out in 183 fresh 
frozen tumor tissue samples. 
The PALB2 gene is a moderate-penetrance breast cancer susceptibility gene with 
approximately fourfold increased risk for the carriers of a truncating mutation. The 1592delT 
mutation was present in 19 familial (2.0%) and 8 sporadic (0.6%) breast cancer patients and 
in 2 (0.2%) population controls. This confirmed the risk effect of the mutation and 
demonstrated a trend of increasing frequency of the mutation with increasing family history 
of breast cancer, with a highly increased risk for familial breast cancer. The tumors of the 
PALB2 mutation carriers were more often of higher grade, expressed higher levels of Ki67 
proliferation marker and were more frequently of the clinically challenging triple negative 
subtype. The PALB2 mutation associated with survival of the familial breast cancer patients 
particularly among HER2 negative cases. An even stronger survival effect was seen in 
patients carrying a BRCA2 mutation, but not among BRCA1 mutation carriers. 
 
 x 
 
The PTEN protein is a negative regulator of the PI3K/Akt oncogenic pathway. Inherited 
inactivating mutations in PTEN cause PTEN hamartomatous polyposis syndromes (PHTS) 
including Cowden syndrome, in which the estimated risk for breast cancer is 25-50%. The 
promoter region in 330 familial breast cancer patients was analyzed for germline genetic 
variation and the genotypes of three low-frequency promoter polymorphisms  
(-903GA, -975GC, and -1026CA) were further determined in 2412 breast cancer patients. All 
three variants significantly associated with decreased survival. The gene expression profiles 
of the breast tumors of promoter variant carriers and non-carriers identified a signature of 160 
differentially expressed genes. The expression of these genes stratified patients into two 
groups with distinct survival patterns supporting the effects of germline variants on gene 
expression signatures and on metastatic development in breast cancer.  
Abnormal translation is a mechanism that frequently occurs during carcinogenesis. A major 
regulator of translation of many cancer-related transcripts is mammalian translation initiation 
factor eIF4E, often overexpressed in various cancers and associated with poor prognosis in 
breast cancer. Here, the eIF4E protein expression was analyzed in breast tumor tissue samples 
using immunohistochemistry. The expression of eIF4E was associated with multiple 
characteristics of aggressive breast cancer and with the triple negative subtype. High 
expression of eIF4E also associated with the survival of breast cancer patients and in 
subgroup analysis a particularly strong effect was identified in patients treated with 
anthracycline-based chemotherapy, whereas in the non-chemotherapy group there was no 
significant survival difference. This is, to our knowledge, the first time eIF4E has been 
associated with treatment outcome in a clinical dataset. These results support eIF4E as a 
prognostic and predictive marker and emphasize the potential of therapies targeting this 
protein. 
Identification of the effects of breast cancer risk mutations on tumor phenotype and patient 
survival can have direct impact on the clinical management of the patients harboring these 
mutations. These patients could benefit from extended and more intense follow-up and more 
aggressive treatment, or preventive measures. The knowledge about the causative genes and 
the genetic variants associated with increased cancer risk, tumor phenotype, and prognosis 
also provide new insights into breast cancer tumorigenesis. 
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1 Introduction 
Breast cancer is the most common cancer in women and family history is among the major 
risk factors of this complex disease, with first degree relatives of a breast cancer patient 
having approximately two-fold increased risk of the disease compared to the general 
population. Inherited factors are also involved in sporadic cases with estimations of having 
some effect in approximately 30% of all breast cancer. Germline variants in multiple loci have 
been associated with breast cancer affecting the disease risk with varying penetrance. Rare 
high-penetrance susceptibility mutations mainly in the BRCA1 and BRCA2 genes substantially 
increase the life-time risk of developing breast cancer. In addition to high-penetrance 
mutations, variants affecting breast cancer risk with moderate or low increase in risk have 
also been identified. The high-penetrance variants are typically rare and lower penetrance 
variants more common in the population. Founder effects of the susceptibility mutations are 
also frequent in certain populations, for example in Finland. 
The prognosis of breast cancer is affected by various factors related to the biological 
properties of the tumor. Numerous prognostic biomarkers have been identified, providing 
information on the outcome of the disease and some also with predictive value by predicting 
the impact of a treatment, such as the expression of estrogen receptor (ER) or HER2, which 
make the tumors responsive for endocrine and anti-HER2 antibody treatments, respectively. 
A need for novel biomarkers remains and they may in the future help to further improve the 
outcome of breast cancer patients. The prognosis of breast cancer also has a heritable 
component but the exact molecular mechanisms have remained largely unknown. The 
plausible mechanisms include for instance the effects of the germline variants on the 
biological properties of tumors or effects carried out through pharmacogenetic functions. 
This study investigates the associations of the Finnish founder mutation 1592delT in the 
moderate-penetrance breast cancer susceptibility gene PALB2 and germline promoter variants 
of the PTEN gene with breast cancer risk, tumor features and patient survival. The study also 
looks into the associations of the translation initiation factor eIF4E protein expression with 
breast cancer tumor features and prognosis with treatment stratified survival analyses.  
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2 Review of the Literature 
2.1 Cancer 
2.1.1 Biology of cancer 
Cells grow, divide, and die under the control of tissue specific regulatory signaling networks 
adjusted by the developmental phase of the organism and the surrounding environmental 
conditions. A cell may escape this control and begin to proliferate with an increased rate to 
form a tumor, and eventually with further malignant transformation, cancer. The development 
of a tumor follows the principals of Darwinian natural selection. The changes in DNA 
introduce cancer cells with adaptations to the environment, and these changes are then 
inherited to the offspring of the cell. In a monoclonal tumor all cells are descendants of the 
cell in which the changes for malignant transformation have occurred (Nowell 1976). 
Through tumor evolution, the tumor cells can adapt to changes affecting their growth, such as 
cancer treatments. A developed tumor may consist of cells of distinct types carrying out 
different functions required for malignant growth, which together with metastatic cells the 
tumor may have released to invade other parts of the body, originate from a common 
ancestor, but may have further developed in different branches of the evolutional tree and 
eventually bear little similarity (Collisson et al. 2012). 
For a tumor to transform into cancer it must develop an ability to proliferate without external 
growth signals from surrounding cells and other tissues, to tolerate growth inhibitory signals, 
and to evade apoptosis. It must develop an unlimited growth potential by preventing the 
shortening of telomers during cell division. When the tumor is growing in size it must secure 
the access of oxygen and nutrition by sustaining angiogenesis. Eventually the tumor develops 
an ability to enter neighboring tissues and to send metastases to other parts of the body. These 
classical hallmarks of cancer (Hanahan, Weinberg 2000) are followed by two new hallmarks 
of reprogramming energy metabolism and evading destruction by the immune system 
(Hanahan, Weinberg 2011). The process to acquire these properties requires changes in 
multiple pathways through mutations and regulatory changes affecting genes in multiple loci. 
This is often made possible, together with inflammation, by increased mutational rate and 
genomic instability of the tumor cells, caused by the changes in the genes controlling genetic 
integrity. 
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DNA is under constant pressure to change by damage caused by endogenous metabolic 
products and external DNA-damaging agents such as oxygen radicals, gamma or ultra violet 
radiation, and mutagenic chemicals. DNA changes can be single-nucleotide changes, small or 
large insertions and deletions, chromosomal translocations, inversions, or changes in the 
overall chromosome number. To prevent accumulation of mutations and to maintain genomic 
integrity, cells possess a wide range of DNA-repair mechanisms. Among the most harmful 
DNA-damages to cell are double strand breaks, which can be repaired with high accuracy by 
using the undamaged strand as a template in the process called homologous recombination 
(HR) DNA repair. Other important double-strand break repair mechanisms are non-
homologous end joining (NHEJ) and single strand annealing (SSA), which are less accurate 
than HR and result in a higher frequency of nucleotide changes in the repaired site. DNA 
single strand breaks can be repaired with the mechanism of base excision repair (BER), 
nucleotide excision repair (NER), and mismatch repair (MMR) (Madhusudan, Middleton 
2005). Alterations in these pathways can lead to an increased mutation rate and further 
mutations in other cancer genes. In addition to mutations changing the DNA sequence, 
epigenetic changes, such as hypermetylation of CpG islands in the regulatory regions of the 
genes, are frequent in affecting the expression of cancer genes in tumors.  
Cancer can originate basically in any type of human tissue. Depending on the type of tissue 
where the cancer originates, the tumors are classified into different categories. Carcinomas, 
for example, originate from epithelial tissues, sarcomas from mesenchymal connective tissue, 
lymphomas from lymphocytes, and leukemias from bone marrow. The different cancers vary, 
however, greatly in their biology, incidence, and outcome. Of the globally estimated number 
of 12.7 million yearly cancer cases, the most common cancer in men is lung cancer and in 
women breast cancer (Jemal et al. 2011). The difference in cancer incidence between 
economically developed and developing countries are large with developed countries having 
higher cancer-incidence rates particularly in cancers related to life-style factors, such as 
smoking, physical inactivity, and diet. In developing countries, cancers related to infections, 
such as stomach and liver cancers associated with Helicobacter pylori and hepatitis B and C 
virus infections, respectively, are more frequent (Jemal et al. 2011). 
Annually 7.6 million people die of cancer (Jemal et al. 2011). The vast majority (90%) of the 
cancer deaths are the result of metastases that the primary tumor has released to invade distant 
tissues in other parts of the body. The biological mechanisms of metastasis are not thoroughly 
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understood, but the process can be organized into two phases: “(i) physical translocation of a 
cancer cell from the primary tumor to the microenvironment of a distant tissue and then (ii) 
colonization” (Chaffer, Weinberg 2011). To be able to form a metastatic tumor in a distant 
site, a population of cells needs to develop an invasive phenotype, leave the primary tumor, 
invade the surrounding tissues, and access circulation. Circulating tumor cells must then 
transit to a distant organ and exit the circulation. They need to evade the immune response of 
the new host tissue and survive as a single cell or as a small cell cluster and finally adapt to 
the new environment and begin to proliferate (Chaffer, Weinberg 2011). Malignancies 
originating in different sites have distinct prognosis with great variation. Cancers in tissues 
like the pancreas or ovaries have in general very poor prognosis since they are often detected 
at a late stage and have had time to develop into a more invasive form, whereas tumors arising 
in more accessible tissues are more often detected in time (Siegel et al. 2012). The 
identification of patient groups with poor prognosis, for instance due to aggressive properties 
of the tumor or weak treatment response, remains one of the major challenges in cancer 
research. 
2.1.2 Cancer genes and mutations 
The cancer genes are genes in which changes in function or expression can lead to cancer 
development. Cancer genes are traditionally classified into oncogenes and tumor suppressor 
genes. Oncogenes act in normal cells as proto-oncogenes having functions mainly in 
regulation of growth, apoptosis, proliferation, and differentiation of cells. Activating 
mutations in proto-oncogenes introduce them with tumor promoting functions. Oncogenic 
mutations affect the tumor dominantly so that the other allele of the gene does not need to be 
changed. These mutations are typically gain-of-function mutations that introduce new 
functions to the gene or cause them to be constantly in active conformation and carry out their 
function out of the control of the regulatory mechanism of gene expression (Varmus 1984). 
The oncogenes are also potential therapeutic targets, and inactivation of even a single 
oncogene is often sufficient to impair cancer cell growth and survival, which is refered to as 
oncogene addiction (Weinstein 2002). 
The other class of cancer genes is tumor suppressor genes, which inhibit the formation of 
tumors. Mutations in tumor suppressors affect the tumor recessively and mutations in them 
are in general inactivating loss of function mutations (Weinberg 2007). Tumor suppressors 
are further classified into two main categories of gatekeeper and caretaker genes (Kinzler, 
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Vogelstein 1997). Of the two, gate keepers are the classical tumor suppressors and they 
regulate the tumor growth directly, for example by regulating cell division, differentiation, 
and apoptosis. Caretaker genes prevent tumor formation by maintaining genomic integrity 
through DNA damage response. Inactivating mutations in these genes lead to an increased 
mutation rate which can cause mutations in, for example, gatekeeper genes and in oncogenes. 
A third class of tumor suppressors are landscapers, which affect tumorigenesis outside the 
tumor from neighboring tissues through intercellular effects (Kinzler, Vogelstein 1998). 
Massively parallel sequencing approaches have recently been applied to produce detailed 
genomic information on various cancers. Tumors typically harbor few driver mutations, 
positively selected in tumor evolution, which causally affect oncogenesis by introducing the 
cancer cell with a growth advantage. A driver mutation is not necessarily required for the 
maintenance of the tumor state, but it has given the tumor the growth advantage at least in one 
point of its evolution. In addition to driver mutations tumors also harbor from tens to more 
than 100,000 unselected, more or less randomly distributed, passenger mutations arising from 
the increased mutation rate. Passenger mutations do not contribute to tumor development, but 
have not been selected out as harmful for the tumor cell either (Stratton et al. 2009). The 
identification of driver mutations from passengers remains a challenge, as remains the 
identification of causal variants in genetics of other traits as well. It is also possible that some 
passenger variants affect the responsiveness of a tumor for a certain treatment, making them 
potential therapeutic targets (Muller et al. 2012).  
The overall number of mutations varies in different cancers. Relatively low numbers are 
typical to cancers occurring at childhood or at early adulthood. A low mutation rate is 
characteristic in medulloblastomas, testicular germ cell tumors, acute leukemias, and in 
carcinoids. A very high number of mutations is typical in cancers which arise due to strong 
mutagenic exposure, such as melanomas affected by ultraviolet light exposure, lung cancer 
affected by tobacco carcinogens, and also in cancers with DNA repair defects, such as 
colorectal or stomach cancers with defective DNA mismatch repair (Stratton 2011, Collisson 
et al. 2012). In addition to mutations, epigenetic changes can drive tumor development 
through mechanisms such as hypermethylation of CpG islands, and chemical modification of 
histones (Esteller 2011a) and through non-coding RNAs (Esteller 2011b), but so far they have 
not been characterized nearly as thoroughly as sequence changes. 
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2.1.3 Hereditary predisposition to cancer 
Family history of the disease is a major risk factor in various cancers and a strong familial 
clustering of cancer cases is often seen among patients. Hereditary cancer, however, only 
accounts for a small proportion of overall cancer incidence, whereas environmental factors are 
the main causative factor (Lichtenstein et al. 2000). In the families with highly increased risk 
for cancer, genetic knowledge can, nevertheless, be of crucial importance by helping to 
identify the tumor at an early stage, and hence reducing the mortality rate of the disease. 
Hereditary cancers tend to occur at an earlier age with multiple primary tumors and definitive 
biological properties (Foulkes 2008). Hereditary factors also play a role in sporadic cancer, 
but do account for a considerably smaller proportion of the overall risk than in cancer 
families. In sporadic cancer the hereditary factors consist of common low-penetrance variants, 
typically increasing the risk by less than 1.5 fold. An increasing number of these common 
polymorphisms have been identified with genome-wide association studies (GWAS) in many 
common cancers with massive sample sets of tens of thousands of cases and controls 
(Fletcher, Houlston 2010). Mutations in high-penetrance genes are typically rare, as they 
would be selected out in evolution and can sometimes be lethal when homozygous. Identified 
low-penetrance alleles have been common in the population studied, and although rare low-
penetrance alleles are likely to exist, they are extremely difficult to study as their detection 
would require a study with a massive sample size. Between the common low-penetrance 
variants and the rare high-penetrance mutations, identified in high-risk cancer families only, 
are moderate-penetrance variants which in general are enriched in cancer families, but are 
also found in sporadic cancer patients and at a low level in unaffected individuals of the 
general population (Foulkes 2008, Fletcher, Houlston 2010).  
In hereditary cancer, mutations in cancer genes are inherited as germline variants which are 
present in all of the cells of an individual, extensively increasing the risk of developing the 
cancers related to those mutations. The hereditary cancer mutations occur nearly always in 
tumor-suppressor genes and hardly ever in oncogenes, as germline oncogene mutations are 
likely to be embryonically lethal (Frank 2001). According to the classical two-hit hypothesis, 
both alleles of a tumor suppressor gene need to be inactivated to induce tumor development 
(Knudson 1971). This is more likely to happen in an individual’s lifetime, if one allele is 
already mutated as a germline variant, than if both alleles would need to be inactivated. Hence 
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the tumor suppressor mutations function on the cellular level recessively, but on the germline 
level, often dominantly.  
The wild-type allele of a mutated cancer gene can be lost with different mechanisms of loss-
of-heterozygosity, for example through deletion of the region, with inactivation through a 
second mutation, or through epigenetic silencing (Foulkes 2008). In addition to the classical 
two-hit hypothesis sometimes only one hit in a tumor suppressor is sufficient for 
tumorigenesis. In the case of haploinsufficiency, the other allele of a gene is inactivated 
through mutation and the other functional allele alone is not enough to carry out the function 
of the gene. Haploinsufficiency can be complete or partial and it can also be dependent on 
tissue type, developmental state, and environmental factors. In dominantly negative cases, a 
mutated allele affects the function of the protein product of the normal allele, accumulating 
the deleterious effect of the mutation. 
2.2 Breast cancer 
2.2.1 Biology and epidemiology 
Breast cancer is the most common cancer in women worldwide with 1.38 million cases 
diagnosed yearly, accounting for 23% of the new cancer cases. It is also the leading cause of 
female cancer mortality, with 458,400 deaths in 2008 (Jemal et al. 2011). In Finland, 4,144 
women were on average diagnosed with breast cancer annually in 2006-2010 and 848 women 
died of breast cancer. Breast cancer is also found in men, but is very rare with approximately 
20 cases yearly in Finland (Engholm et al. 2012). Breast cancer is a complex disease with 
multiple known risk factors, many of which are related to the breast tissues’ exposure to the 
hormone estrogen. These are early age of menarche, late age at menopause, a low number of 
pregnancies, a short-term of breast feeding, and use of post-menopausal hormone replacement 
therapies (Fasching et al. 2011). Every year younger age at menarche increases the breast 
cancer risk by a factor of 1.05, and every year older at menopause increases risk by a factor 
1.03 (Collaborative Group on Hormonal Factors in Breast Cancer 2012). The risk decreases 
by 7% for every child birth, and by 4% for every 12 months of breast feeding (Collaborative 
Group on Hormonal Factors in Breast Cancer 2002). Other risk factors include 
mammographic density, postmenopausal obesity, and alcohol consumption (Fasching et al. 
2011). Family history of the disease is also a major risk factor, with the risk compared to 
women with no affected first degree relatives increasing by a factor of 1.80 for one, 2.93 for 
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two, and 3.90 for three or more first degree relatives with breast cancer (Collaborative Group 
on Hormonal Factors in Breast Cancer 2001). 
The human breast consists of fat, connective tissue, and glands that are divided to lobes, 
which are connected towards the nipple by milk ducts. Breast cancers originate from the 
breast epithelium, classifying them as carcinomas. Breast cancers are further classified as 
ductal, if they resemble the epithelial cells lining the milk ducts, and lobular if they resemble 
the cells of the breast lobules. Ductal carcinoma is the most common type, accounting for 70-
80% of cases, and lobular accounting for approximately 10%. Other more rare types are 
medullar, tubular, papillary, and mucinous breast cancers (Berg, Hutter 1995). In clinical use, 
breast cancers are classified into different stages based on the tumor size (T), involvement of 
the disease in lymph nodes (N), and distant metastasis (M) (Sainsbury et al. 2000). The TNM 
staging strongly determines the prognosis and is used in the assessment of treatment. Another 
clinically important feature of breast tumors is differentiation, which is categorized into three 
grades based on tubule formation, nuclear pleomorphism, and mitotic count, with grade I 
tumors being well, grade II tumors moderately, and grade III tumors poorly differentiated 
(Elston, Ellis 1991).  
A major molecular classifier of breast cancer is the expression of estrogen and progesterone 
hormone receptors, ER and PgR, respectively, in the tumor. The expression of these two 
receptors is strongly correlated with each other and up to 80% of breast cancers are ER 
positive. The risk factors and biological background for ER negative breast cancer are distinct 
from ER positive (Duffy 2005). Another molecular classifier of breast cancer is the 
overexpression of the oncogenic HER2 protein, often through somatic amplification of a 
genomic region on chromosome 17q containing the ERBB2 gene, which is a major driver 
event in 10-34% of breast cancers (Ross et al. 2003). 
The proliferation rate of tumor cells can be evaluated  by assessing the expression levels of 
proliferation markers, such as Ki67, which is present in proliferating tissues, but absent in 
quiescent cells. It is also an important prognostic factor (de Azambuja et al. 2007). The 
somatic TP53 mutation is a major driver event in approximately 35% of breast cancer (Cancer 
Genome Atlas Network 2012). The mutated p53 protein accumulates in cancer cells and can 
be assessed with immunohistochemical analyses of the protein levels (Borresen-Dale 2003). 
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In addition to conventional protein markers, gene expression signatures based on microarray 
data have been applied to divide breast cancers into different groups of so-called intrinsic 
subtypes, namely luminal A, luminal B, HER2+, normal-like, and basal (Perou et al. 2000, 
Sorlie et al. 2001). These subtypes are partly correlated with the conventional markers, with 
luminal subtypes being ER positive, and further separated into luminal A and B with the 
expression of proliferation-related genes being more frequently overexpressed in the latter.  
HER2+ tumors are typically ER negative and HER2 positive. Basal cancers are often negative 
for ER and HER2 and express basal cytokeratines and EGFR (epidermal growth factor 
receptor). The normal-like subtype resembles normal breast tissue and might, at least partly, 
be explained by contamination of the tumor sample by normal tissue. Recently even more 
specific subtypes have been characterized through gene expression profiling combined with 
copy number variation, classifying breast cancers into 10 categories with survival patterns 
specific to each group (Curtis et al. 2012). 
2.2.2 Prognosis and treatment 
Although the incidence of breast cancer has been increasing, the mortality rate of the disease 
has been decreasing since early 1990s (DeSantis et al. 2011). Early diagnosis improves the 
outcome, and screening programs have been successful in identifying cases at an early stage. 
Development of more efficient treatments has also had its effect on the improvement of 
outcome. 
The primary treatment for breast cancer is surgery, either mastectomy, in which the whole 
breast is removed, or removal of the tumor only with a margin of surrounding healthy tissue. 
If the regional lymph nodes are affected, they are also removed. Neoadjuvant, or preoperative, 
chemotherapy or hormonal treatment can be used to reduce the size of the tumor. Following 
the surgery, radio therapy can be administered on the site of the tumor and regional lymph 
nodes in patients with high risk of local recurrence of the tumor. Radiotherapy reduces the 
risk for local or distant recurrence of the disease within 10 years by 15.7% (from 35.0% to 
19.3%) and the risk of breast cancer death by 3.8% (Early Breast Cancer Trialists' 
Collaborative Group (EBCTCG) et al. 2011a).  
Systemic adjuvant treatments, such as chemotherapy and endocrine therapy, may be 
administered in cases with increased risk of recurrence to destroy micrometastatic cancer 
cells. Adjuvant therapies considerably decrease the risk of recurrence and improve the 
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survival of the patients, although even severe side effects are not uncommon.  Chemotherapy 
is usually applied as polychemotherapy with a combination of different drugs, for example as 
a combination of cyclophosphamide, methotrexate and fluorouracil (CMF) or as CEF, in 
which methotrexate has been replaced with an epirubicine anthracycline. Anthracycline-based 
treatments have been the most widely used chemotherapy for breast cancer. Taxanes, such as 
docetaxel, are increasingly added, as they lack cardiotoxicity and improve efficacy compared 
to anthracycline-alone regimens (Giordano et al. 2012). Poly-chemotherapy reduces the 10 
year breast cancer mortality rate by approximately a third (Early Breast Cancer Trialists' 
Collaborative Group (EBCTCG) et al. 2012). 
Other important systemic adjuvant treatments in breast cancer are endocrine therapies, 
effective in hormone receptor positive cancers, in which estrogen is a major growth factor. 
Endocrine treatment is used as anti-estrogens (tamoxifen) for both pre- and post-menopausal 
patients or in post-menopausal patients as inhibitors of aromatase enzyme, which synthesizes 
estrogen. If tamoxifen is not suitable for a patient, ovarian ablation, by suppressing the 
ovarian function, can also be applied. Tamoxifen treatment reduces the 15 year breast cancer 
mortality approximately by 30% and breast cancer recurrency by 15% (Early Breast Cancer 
Trialists' Collaborative Group (EBCTCG) et al. 2011b). Aromatase inhibitors can, in post-
menopausal women, prolong the disease-free survival even more than tamoxifen (Howell et 
al. 2005, Cuzick et al. 2010). 
Finally, HER2 positive tumors can be effectively treated with the systemic HER2 protein-
targeting monoclonal antibody trastuzumab, which considerably improves patient survival 
and decreases the tumor size (Romond et al. 2005, Piccart-Gebhart et al. 2005, Joensuu et al. 
2009, Stern 2012).  Novel treatments targeting HER2 and other members of the HER family 
with different mechanisms, for example through other monoclonal antibodies, tyrosine kinase 
inhibitors, and immunostimulation, are being developed (Arteaga et al. 2011). 
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2.3 Genetics of breast cancer susceptibility 
2.3.1 High-penetrance breast cancer susceptibility genes 
2.3.1.1 BRCA1 and BRCA2 
The most well-known susceptibility genes for hereditary breast cancer are the BRCA1 (Miki 
et al. 1994) and BRCA2 (Wooster et al. 1995). Women with mutations in BRCA1 have 
approximately a 57% risk for breast cancer and a 40% risk for ovarian cancer and women 
with mutations in BRCA2 have a 49% risk for breast cancer and an 18% risk for ovarian 
cancer by the age of 70 (Chen, Parmigiani 2007). This risk estimation, however, varies 
between sample sets and populations, with higher risks seen usually in family based studies 
already selected for increased risk, possibly through other modifying variants. For rare male 
breast cancer, men with a BRCA1 mutation have a risk of 1.2% and men with a BRCA2 
mutation have a risk of 6.8% (Tai et al. 2007). The mutation carriers of BRCA1 and BRCA2 
are at increased risk of developing pancreatic cancer, but the risk effect is small. BRCA1 
mutation carriers also have slightly increased risk, and BRCA2 mutation carriers moderately 
increased risk, of prostate cancer. Some BRCA2 families may also have elevated risk for 
melanoma (Levy-Lahad, Friedman 2007). 
BRCA1 and BRCA2 mutations are very rare in the general population, and in breast cancer 
patients unselected for family history they are found in with a low frequency of 0-7% for 
BRCA1 and 1-3% for BRCA2 (Fackenthal, Olopade 2007). The Breast Cancer Information 
Core database lists currently 894 BRCA1 and 824 BRCA2 pathogenic mutations, of which 
most are found in single families. Strong founder effects are also seen for example in Finnish, 
Icelandic, and Ashkenazi Jewish populations (Ferla et al. 2007). A vast majority of the 
mutations truncate the protein product by causing a premature termination of translation. 
Small insertions and deletions causing frameshifts, nonsense, and splice site mutations 
account for the majority of the changes, and particularly in the case of BRCA1, large 
insertions and deletions are common due to the large number of alu-mediated rearrangement 
hotspots in the introns of the gene. Pathogenic missense mutations are rare (Fackenthal, 
Olopade 2007). Bi-allelic mutations of BRCA1 and BRCA2 are embryonically lethal in mouse 
models (Gowen et al. 1996, Suzuki et al. 1997), and no bi-allelic BRCA1 mutation carrier has 
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been identified in humans. Human bi-allelic mutations in BRCA2 cause Fanconi anemia 
subtype FA-D1 (Howlett et al. 2002) (see 2.3.2).   
Breast cancers of BRCA1 and BRCA2 mutation carriers occur at an early age and are more 
often bilateral compared to those of familial or unselected non-carriers. Breast tumors of 
BRCA1 mutation carriers tend to have histopathological features that are different from non-
carrier tumors, but in BRCA2 mutation carriers, the tumors are more heterogeneous and 
cannot as clearly be differentiated from non-carrier tumors. BRCA1-related breast tumors are 
more often higher grade (poorly differentiated), and negative for ER and HER2 status. They 
are often highly proliferative, harbor somatic TP53 mutations, and over-present the rare 
medullary histology (Honrado et al. 2006). Somatic mutations in BRCA1 or BRCA2 are not 
common in breast cancer, except in triple negative or basal tumors (Cancer Genome Atlas 
Network 2012). Epigenetic silencing through hypermethylation of the promoter region of 
BRCA1, however, has been detected in sporadic breast cancer (Esteller et al. 2000).  
The BRCA1 and BRCA2 proteins are major regulators of the homologous recombination 
(HR) DNA double strand break repair machinery; a function they carry out through a complex 
network of interactions with other proteins (Venkitaraman 2002). This classifies them as 
caretaker tumor suppressors. BRCA1 can form at least three different functional complexes 
through its BRCT domain: (i) a complex with abraxas and RAP80, which further interacts 
with H2AX, RNF8 and MDC1, detecting DNA damage; (ii) a complex with CtiP, which 
further connects with the NMR complex (NBS1-MRE11-RAD50), also functioning as a 
sensor for DNA-damage; (iii) a complex with BRIP1 and TOPBP1, which further attach to 
CHK1 and ATR, functioning in DNA repair during replication (Roy et al. 2011).  
Furthermore, BRCA1 interacts through its coiled-coil-domain with PALB2, which further 
interacts with BRCA2, hence linking the two BRCA proteins together. BRCA1 is also 
involved in estrogen dependent cell proliferation by inhibiting ER-alpha signalling (Fan et al. 
1999), and in X-chromosome inactivation (Buller et al. 1999). It participates in cell cycle 
regulation, is a part of the RNA-polymerase II holoenzyme (Scully et al. 1997), and interacts 
with the components of the histone-deacetylation complex (Yarden, Brody 1999). 
The interactions of BRCA2 are not as versatile as those of BRCA1, with its main functional 
interaction directly related to HR with RAD51 through the BRC domain. It also interacts with 
PALB2, which stabilizes BRCA2 and participates in its localization to the site of DNA 
damage (Roy et al. 2011). 
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2.3.1.2 Cancer syndromes 
Highly increased risk of breast cancer is also characteristic in certain rare dominant autosomal 
familial cancer syndromes, most notably in Li-Fraumeni syndrome (Malkin et al. 1990), 
Cowden syndrome (Eng 2003b), and Peutz-Jeghers syndrome (Hemminki et al. 1998), caused 
by mutations in TP53, PTEN, and LKB1 genes, respectively. Li-Fraumeni syndrome is 
characterized by various cancers with early onset, including sarcomas in bone and soft tissue, 
leukemias, as well as breast, brain, and adrenal cortex tumors. Of the female Li-Fraumeni 
patients, 28-56% develop breast cancer by the age of 45 years. Of the families diagnosed with 
the syndrome, a mutation in TP53 gene has been identified in 70%. These mutations are 
typically missense changes, similar to somatic mutations found in TP53, with a dominant 
negative function (Malkin et al. 1990). 
Cowden syndrome is a hamartomatous polyposis syndrome with increased risk of 
malignancies particularly in the thyroid, endometrium, and breast. Life-time risk of breast 
cancer in Cowden syndrome patients is estimated to be 25-50% (Eng 2003a). Cowden 
syndrome is caused by inherited mutations in the PTEN gene (Nelen et al. 1996, Liaw et al. 
1997), which are also associated with Bannayan-Riley-Ruvalcaba syndrome and Proteus 
syndrome (Eng 2003a). Together these diseases can be classified as PTEN-related hamartoma 
syndromes (PTHS). Recently, activating germline mutations in PIK3CA and AKT, the proto-
oncogenes PTEN is regulating, have also been identified in PTHS patients (Orloff et al. 
2013). This finding is particularly remarkable as all oncogenenic germline mutations are 
extremely rare. For more detailed description of the role of PTEN in tumor suppression see 
2.6. 
Another hamartomatous polyposis syndrome with increased risk of breast cancer is Peutz-
Jeghers syndrome (PJS), characterized by hamartomatous polyps in the gastrointestinal tract 
and melanin pigmentation of the lips. PJS patients have increased risk of cancer in the 
gastrointestinal track, pancreas, breast, and gynaecological sites. The risk of developing breast 
cancer by the age of 70 is 50% (Hearle et al. 2006). PJS is caused by rare mutations in the 
LKB1/STK11 gene (Hemminki et al. 1998). 
Finally, mutations in the CDH1 gene, coding for the E-cadherin protein, cause hereditary 
diffuse gastric cancer and lobular breast cancer (Schrader et al. 2008). The lifetime risk of 
CDH1 mutation carriers to develop lobular breast cancer is between 39-52%.  
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2.3.2 Moderate-penetrance breast cancer susceptibility genes 
Ataxia telengiectasia (AT) is a recessive disease caused by bi-allelelic mutations in the ATM 
gene (Savitsky et al. 1995). The disease is characterized by neuronal degeneration, 
immunodeficiency, sensitivity to radiation, and strongly increased tumor susceptibility. The 
cancers of AT patients arise mainly in tissues of lymphoid origin. The ATM protein is a 
serine/threonine kinase, which participates in the repair of DNA double strand break 
signalling and interacts with many tumor suppressors such as p53, BRCA1, and BRCA2 
(Derheimer, Kastan 2010). Heterozygous mutations in the ATM gene increase the risk of 
breast cancer by approximately two-fold, although higher risk estimates have also been 
proposed (Ahmed, Rahman 2006). The low frequency of mutations has made exact risk 
estimation challenging.  
Another recessive syndrome genetically related to breast cancer is Fanconi anemia (FA), a 
rare disorder in which patients suffer from various developmental abnormalities, bone marrow 
failure, sensitivity to radiation, genomic instability, and congenital defects, and have highly 
increased risk of various cancers (Auerbach 2009). Fanconi anemia consists of different 
subtypes originating in bi-allelic mutations in several DNA-repair genes including many 
which functionally interact with BRCA1 and BRCA2. At least 15 different genes (FANCA, 
FANCB, FANCC, FANCD1/BRCA2, FANCD2, FANCE, FANCF, FANCG, FANCI, 
FANCJ/BRIP1, FANCL, FANCM, FANCN/PALB2, FANCO/RAD51C, and FANCP/SLX4) are 
known to cause distinct FA subtypes, when bi-allelically mutated (de Winter, Joenje 2009, 
Soulier 2011). Of the FA genes, four, FANCD1/BRCA2, FANCJ/BRIP1 FANCN/PALB2, and 
FANCO/RAD51C are also associated with breast cancer susceptibility, when only one of the 
alleles is mutated. BRCA2 and PALB2 function in close interaction, and hence the similar FA 
phenotype is not surprising. PALB2 is a moderate-penetrance breast cancer susceptibility gene 
with the estimated increased risk of breast cancer varying from 2.3-fold (Rahman et al. 2007) 
to up 6-fold (Erkko et al. 2008), with the true risk likely being somewhere between the results 
of the two studies. 
Monoallelic mutations in FANCJ, also known as BACH1, or BRIP1, are associated with two-
fold increased risk of breast cancer (Seal et al. 2006). Bi-allelic mutations in a RAD51 
paralog gene RAD51C have been identified to account for Fanconi anemia-like disorder (Vaz 
et al. 2010). The monoallelic mutations in RAD51C were also proposed to make it a breast 
cancer and ovarian susceptibility gene (Meindl et al. 2010), but later we (Pelttari et al. 2011) 
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and others (Loveday et al. 2012) have shown it to be mainly an ovarian cancer risk gene, with 
breast cancer only occurring in families also affected with ovarian cancer, a far more rare 
malignancy than breast cancer. Another RAD51 paralog RAD51D is also an ovarian cancer 
risk gene (Loveday et al. 2011). 
CHEK2 (Cell Cycle Checkpoint Kinase 2) is involved in the DNA double strand break 
response by controlling the cell cycle at several checkpoints, and through interactions with 
proteins of apoptosis and DNA repair machinery (Bartek, Lukas 2003). A heterozygous 
truncating mutation 1100delC in the CHEK2 gene has been identified as a breast cancer 
susceptibility mutation in many countries, and it is also present in the general population with 
the highest genotype frequencies seen in the Dutch with 1.3-1.6% (Meijers-Heijboer et al. 
2002) and in Finns with 1.4% (Vahteristo et al. 2002). The mutation approximately doubles 
the risk of breast cancer, but may confer even higher risk in women with a family background 
of the disease (Nevanlinna, Bartek 2006). Homozygous individuals have also been identified 
and may have a highly increased risk for breast cancer (Adank et al. 2011). Other truncating 
variants in the CHEK2 gene have also been identified with similar effects on breast cancer 
predisposition (Cybulski et al. 2011). A missense variant, I157T, common in northern and 
Eastern Europe, with a genotype frequency of 5.3% in Finland, also associates with breast 
cancer risk, but with lower penetrance than the truncating variants, increasing the risk for 
breast cancer approximately 1.5 fold (Kilpivaara et al. 2004, Nevanlinna, Bartek 2006). 
The number of moderate, but also high-penetrance, variants is likely to grow substantially in 
the near future as targeted deep sequencing, whole exome sequencing, and eventually whole 
genome sequencing projects begin to reveal novel rare variants in cancer families. Indeed, 
targeted sequencing approaches have identified mutations in known susceptibility genes 
(Walsh et al. 2010), and recently exome sequencing has suggested XRCC2 to be a breast 
cancer susceptibility gene (Park et al. 2012) and proposed the same for the FANCC and BLM 
genes (Thompson et al. 2012). These findings, however, require rigorous validation in 
independent patient cohorts, a process often neglected in traditional candidate gene studies as 
well, and, according to a more recent study, the XRCC2 variants do not seem to play a major 
role in familial breast cancer predisposition (Hilbers et al. 2012). The risk estimations and 
related cancer syndromes of the high and moderate-penetrance breast cancer predisposing 
genes are summarized in Table 1. 
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Table 1. High and moderate-penetrance breast cancer susceptibility genes with cancer syndromes they 
relate to and estimated risk ratios (RR) (Mavaddat et al. 2010). 
Gene Locus Related syndrome RR 
BRCA1 17q21 
 
5-45 
BRCA2 13q12.3 Fanconi anemia (D1) 9-21 
TP53 17p13.1 Li-Fraumeni 2-10 
PTEN 10q23.1 Cowden 2-10 
LKB1/STK11 19p13.3 Peutz-Jeghers 2-10 
CDH1 16q22.1 
 
2-10 
ATM 11q22.3 Ataxia telengiectasia 2-3 
BRIP1 17q22 Fanconi anemia (J) 2-3 
PALB2 16p12.1 Fanconi anemia (N) 2-4 
CHEK2 22q12.1 
 
2-3 
 
2.3.3 Low-penetrance breast cancer susceptibility genes 
A low increase in breast cancer risk has been associated with numerous variants, identified 
mostly through GWAS and also on a smaller scale, through a candidate gene approach. These 
variants are typically common in the population and contribute to less than two-fold increased 
risk of the disease (Fletcher, Houlston 2010). Effects this small require large case-control 
sample sets and most of the successful studies have been carried out by international 
consortia, with up to tens of thousands subjects for multi-stage validation. Indeed, many 
reported associations in single studies have later proven to be false findings when studied in 
larger independent data sets. The GWAS studies depend on a tagging approach in which 
SNPs are in linkage disequilibrium (LD) with each other and therefore the risk variant 
identified cannot be expected to be the actual causative variant. The identification of the 
causative variant requires fine mapping of the risk locus region and further functional studies. 
Some of the risk variants, furthermore, localize far away from any known gene in so-called 
gene deserts, which makes the causative gene hard to identify. Most of the common risk 
variants are likely regulatory variants affecting the expression levels of their target genes. As 
these effects are likely to be modest also at the molecular level, and as the high frequency in 
population indicates no major evolutionary disadvantage, functional studies can also be 
challenging. 
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The first low-penetrance risk variants identified for breast cancer susceptibility with strong 
validation in large independent data sets were two common missense variants from a 
candidate SNP study: D302H (rs1045485) in the Casp8 gene with a slight reduction of the 
risk, and L10P (rs1982073) in the TGFB1 gene with a slight increase of risk (Cox et al. 2007). 
Shortly after, the first breast cancer GWAS reported five susceptibility loci, in 5q11.2 near the 
MAP3K1 gene, 8q24.2 in an intergenic region upstream of the MYC gene, 10q26.1 in the 
intron two of the FGFR2 gene, 11p15.5 near the LSP1 gene, and 16q12.1 close to the 
TOX3/TNRC9 gene (Easton et al. 2007). To date, variants in altogether 28 loci have been 
found in genome-wide association studies to be associated with breast cancer risk with high 
probability (National Cancer Institute 2012). Many associations are stronger in, or even 
specific to, ER positive or ER negative disease, and some associations are only detected in 
Asian or European populations. Some common susceptibility variants are also associated with 
breast tumor subtypes defined by ER, PgR, HER2, CK5/6, and EGFR status (Broeks et al. 
2011). No interactions between the genetic variants and the non-genetic risk factors have so 
far been confirmed, possibly due to the need for a considerably larger sample size to 
statistically power such analyses (Campa et al. 2011, Milne et al. 2010).  The common 
variation, furthermore, modifies the breast cancer risk of BRCA1 and BRCA2 mutation 
carriers, with different risk variants involved between the mutation carriers of the two genes 
(Milne, Antoniou 2011). 
2.4 Genetics of breast cancer survival 
Population-based registry studies from Sweden have shown that a heritable component exists 
not only for breast cancer risk but also for the prognosis of the disease (Hartman et al. 2007, 
Lindstrom et al. 2007, Hemminki et al. 2008). The outcome of a breast cancer patient 
significantly predicts the outcome of breast cancer of her daughters and sisters with a hazard 
ratio (HR) of 1.6 (95% CI, 1.1-2.3) for daughters and 1.8 (95% CI, 1.0-3.4) for sisters 
(Hartman et al. 2007). A significantly worse survival rate is also seen in children of parents 
with poor survival of colorectal, lung, and prostate cancer (Lindstrom et al. 2007). Further 
evidence for inherited predisposition to cancer outcome has been produced through mouse 
studies, with the observation that different strains of mice also have different features of 
mammary tumor progression (Lifsted et al. 1998). The molecular mechanisms behind the 
familial component of breast cancer survival are still largely unknown. In addition to 
hereditary variation, giving the tumor a more malignant phenotype at some point during its 
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evolution and hence affecting the patient survival, the prognostic effect can also be caused by 
altered response to treatment through, for instance, differences in drug metabolism (Wang et 
al. 2011). 
The effects of BRCA1 and BRCA2 mutations on breast cancer prognosis have been under 
investigation in various studies but the results have been inconclusive. Some studies have 
found no difference between the survival of BRCA1 and BRCA2 mutation carriers compared 
to non-carriers (Bonadona et al. 2007, Brekelmans et al. 2007, Rennert et al. 2007) but others 
have found BRCA1 mutations to be associated with worse survival (Robson et al. 2004, 
Moller et al. 2007, Lee et al. 2010). The number of BRCA2 mutation carriers, however, has 
been very limited in these studies, affecting the power to reliably detect any possible survival 
effect (Lee et al. 2010, Bordeleau et al. 2010), but a recent study has, however, found 
associations between these mutations and worse prognosis (Goodwin et al. 2012). In ovarian 
cancer, both BRCA1 and BRCA2 mutation carriers have, interestingly, a better prognosis than 
the non-carriers, possibly through better response to chemotherapy by DNA damaging agents 
(Bolton et al. 2012). 
The roles other major breast cancer predisposing genes might play in patient survival remain 
largely unknown. The low frequency of mutations makes survival analyses challenging as the 
number of events required for survival analyses is often insufficient. The CHEK2 1100delT 
mutation, with a relatively high allele frequency in many populations, has, however, been 
associated with a 1.4-fold increased risk of early death, 1.6-fold increased risk of breast 
cancer death, and 3.5-fold increased risk of second breast cancer in ER positive breast cancer 
patients (Weischer et al. 2012). The low-penetrance risk variants do not seem to be behind 
breast cancer survival predisposition either. Of the 11 known risk SNPs and 62 other 
candidate or GWAS related SNPs, only one, rs3803662 at the 16q12.1 locus close to the 
TOX3/TNRC9 gene, was found to be associated with breast cancer survival in a recent large 
consortium study, with a HR of 1.21 for overall and 1.29 for breast cancer specific survival 
for the patients with the rare homozygous genotype (Fasching et al. 2012). 
Only a few genome wide association studies have so far been carried out for breast cancer 
survival. In two studies of breast cancer patients with European ethnicity, no association was 
detected in the first study (Azzato et al. 2010a), but the second study suggested an association 
between improved survival and rs4778137 in the OCA2 gene (Azzato et al. 2010b). A recent 
Chinese study identified two SNPs associated with breast cancer survival: rs3784099 on 
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chromosome 14 in intron 7 of the RAD51L1/RAD51B gene and rs9934948 on chromosome 16 
(Shu et al. 2012). A low-penetrance risk SNP, rs999737, not in LD with the survival SNP, has 
also been identified in RAD51L1 (Thomas et al. 2009). Another recent study from Japan 
identified an association between rs10509373 in the C10orf11 gene on chromosome 10q22 
and breast cancer recurrence-free survival in patients treated with tamoxifen (Kiyotani et al. 
2012), although the sample set in this study was rather limited in size.  
A great number of studies have been published reporting single genetic associations with 
breast cancer survival, most of which have not been validated in independent datasets. Many 
studies have been focusing on single candidate genes or variants and some have focused on a 
larger number of genes, for example within a shared pathway. One example of a suggested 
treatment response effect is the association of CYP2D6 variants and breast cancer prognosis 
through effects on tamoxifen metabolism and treatment response of ER positive tamoxifen-
treated patients (Hoskins et al. 2009). Another example is the effect of a missense variant 
P187S in the NQO1 gene on the response to epirubicin chemotherapy (Fagerholm et al. 2008).  
2.5 PALB2 
The PALB2 gene on chromosome 16p12.2 is a major moderate-penetrance breast cancer 
susceptibility gene (Rahman et al. 2007) in which mutations are also associated with familial 
pancreatic cancer (Jones et al. 2009). Unlike BRCA2 mutations, the PALB2 mutations do not 
seem to play a role in prostate (Tischkowitz et al. 2008, Pakkanen et al. 2009) or ovarian 
cancer predisposition (Tischkowitz, Xia 2010), but they have been associated with increased 
risk of male breast cancer (Casadei et al. 2011). Bi-allelic mutations in the PALB2 gene cause 
Fanconi anemia subtype N, as described earlier in 2.3.2 (Xia et al. 2007, Reid et al. 2007), 
with resemblance to the clinical features of Fanconi anemia subtype D1 caused by the bi-
allelic BRCA2 mutations with high risk of embryonic tumors (Tischkowitz, Xia 2010). 
Truncating PALB2 mutations have been found in breast cancer families in British (Rahman et 
al. 2007), Finnish (Erkko et al. 2007), French Canadian (Foulkes et al. 2007), Ashkenazi 
Jewish (Tischkowitz et al. 2007), Spanish (Garcia et al. 2008), Chinese (Cao et al. 2008), 
South African (Sluiter et al. 2009), Italian (Papi et al. 2010, Balia et al. 2010), Polish 
(Dansonka-Mieszkowska et al. 2010), Australian  (Southey et al. 2010, Wong et al. 2011, Teo 
et al. 2013a, Teo et al. 2013b), American (Casadei et al. 2011), German (Hellebrand et al. 
2011, Bogdanova et al. 2011, Pern et al. 2012), Russian (Bogdanova et al. 2011), and African 
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American (Zheng et al. 2012) populations. The confirmed pathogenic mutations have so far 
been protein truncating. The vast majority of the identified mutations have only been 
identified in single families, but recurrent mutations are also known. The most frequent 
founder mutation is the Finnish mutation 1592delT, causing a frameshift at leusine residue 
531 and a premature stop codon (Erkko et al. 2007). The mutation was originally found to be 
present in 2.7% of familial breast cancer patients (n=113), 0.9% of unselected patients 
(n=1918), and in 0.2% of population controls (n=2501). The risk effect of PALB2 mutations 
varies depending on the study, from a 2.3-fold increase in the original study identifying 
PALB2 as a breast cancer susceptibility gene (Rahman et al. 2007), up to 6-fold risk when 
using segregation analysis with the Finnish founder mutation (Erkko et al. 2008), an effect 
comparable to BRCA2 mutations. Both estimations are based on a very limited set of mutation 
carriers, making the results unspecific, and particularly the result of the segregation analysis 
seems an overestimation, biased by its concentration only on a small number of high risk 
families. Large international collaborative studies are required to reliably estimate the PALB2 
risk in breast cancer and indeed such projects are on-going by the PALB2 Interest Group. 
The PALB2 protein (Figure 1) consists of 1,186-amino acids and has a coiled-coil motif at the 
N-terminal region, with which it interacts with BRCA1, and WD repeats at the C-terminal 
region forming a β-propeller structure, which interacts with BRCA2 (Xia et al. 2006, 
Tischkowitz, Xia 2010). The third protein interacting with PALB2 is MRG15 coded by the 
MORF4L1 gene, having a binding motif with amino acids 611-764 on PALB2 (Sy et al. 
2009a). No mutations in the MORF4L1 gene have, however, been found in breast cancer 
families (Rio Frio et al. 2010). The main function of the PALB2 protein is to stabilize BRCA2 
and to participate in its localization to the site of DNA damage, with approximately 50% of 
BRCA2 bound to PALB2 (Xia et al. 2006). PALB2 also physically links BRCA1 and BRCA2 
together, demonstrating that these proteins work together in HR, joined also by RAD51 (Sy et 
al. 2009b, Dray et al. 2010). The Palb2
(+/-)
 mice do not have a particular phenotype and 
remained tumor free for the follow-up time of 8 months. Palb2
(-/-)
 mice, however, died during 
embryogenesis with multiple developmental abnormalities, resembling the Brca1 and Brca2 
knock-out mice (Rantakari et al. 2010). The loss of p53 in Palb2 knock-out mice lessened the 
phenotype, but did not prevent the embryonic lethality (Bouwman et al. 2011). 
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Figure 1. A diagram of the structure of the PALB2 protein with known functional domains and 
regions binding with interacting proteins. Adapted from (Tischkowitz, Xia 2010). 
How PALB2 mutations affect carcinogenesis has remained uncertain. Loss of heterozygosity 
(LOH) of the wild type PALB2 allele has been identified with inconclusive results in different 
studies, with earlier studies reporting no LOH (Erkko et al. 2007, Tischkowitz et al. 2007) 
(with five and four tumors analyzed), but later studies have reported it in all tumors analyzed 
(Garcia et al. 2008, Casadei et al. 2011)(with one and seven tumors analyzed). The dominant 
negative effect of the truncating mutations with the proteins’ HR functions does not seem to 
be the mechanism, although other dominantly negative effects cannot be excluded 
(Tischkowitz, Xia 2010). Inactivation of the wild type PALB2 allele through somatic mutation 
has been identified in a PALB2-related pancreatic cancer case (Jones et al. 2009) and somatic 
bi-allelic PALB2 mutation has been reported in a lobular breast cancer case (Shah et al. 2009), 
although somatic PALB2 mutations do not seem to be common in breast cancer (Cancer 
Genome Atlas Network 2012). So far the breast tumors of germline PALB2 mutation carriers 
have not been analyzed for somatic PALB2 mutations, but the second hit through mutation or 
epigenetic silencing of the wild type allele could be a plausible mechanism. Indeed, 
hypermethylation has been detected in the promoter region of PALB2 in sporadic and familial 
breast cancer and in ovarian cancer, affecting the PALB2 expression levels (Potapova et al. 
2008). 
The characteristics of the breast tumors of PALB2 carriers had prior to this work been 
analysed only in small number of tumors (Erkko et al. 2007, Foulkes et al. 2007, Tischkowitz 
et al. 2007, Garcia et al. 2008, Cao et al. 2008). The overall trend towards triple negative 
tumors, however, has been evident. The effects of PALB2 mutations on survival of the 
patients had not been investigated prior to this study. 
 
PALB2 1186aa
Coiled-coil WD repeats/β-propeller
BRCA1 MRG15 BRCA2/RAD51
 22 
 
2.6 PTEN 
The PTEN protein, a dual specificity phosphatase capable of dephosphorylating both lipids 
and proteins, is a gatekeeper tumor suppressor, and a key regulator of the activation of the 
PI3K/AKT oncogenic pathway (Cantley, Neel 1999). The main mechanism of activation of 
this pathway is the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) into 
phosphatidylinositol 3,4,5-trisphosphate (PIP3), catalysed by phosphatidylinositol-3-kinase 
(PI3K). The binding of PIP3 to AKT allows phosphoinositide dependent kinase 1 (PDK1) to 
activate AKT through phosphorylation. Actived AKT can then further activate its various 
targets, related, for example, to cell growth and proliferation (Salmena et al. 2008, Song et al. 
2012). In normal conditions the amount of PIP3 is regulated by PTEN, which dephophorylates 
it back to PIP2 and hence limits the activation of AKT (Vivanco, Sawyers 2002). Inactivating 
mutations or chromosomal loss of the PTEN gene, or activating mutations in genes coding 
PI3K components, most commonly PIK3CA for subunit p110α and PIK3CB for subunit p85α, 
or in AKT1, cause the pathway to be constantly activated and contribute to the development of 
cancer (Miller et al. 2011). The alterations of the PI3K pathway seem to be involved in the 
majority (59%) of sporadic breast tumors (Jones et al. 2013). PTEN also has independent 
functions outside PI3K/AKT regulation, most notably the negative regulatory functions of the 
MAPK pathway (Gu et al. 1998). It can be localized in the nucleus through different 
mechanisms, where it regulates chromosomal stability, acetylates p53, and participates in the 
DNA-damage response and in the induction of apoptosis (Salmena et al. 2008, Yin, Shen 
2008, Planchon et al. 2008, Song et al. 2012). 
The PTEN gene is located on chromosome 10q23 and it consists of nine exons which code for 
a 403 amino acid residue protein (Li et al. 1997, Steck et al. 1997). The promoter of PTEN is 
located 5’ region of the gene between the nucleotides -1344 and -747 from the translation 
start site (Figure 2), containing binding sites to transcription factors such as p53, Sp1, and 
Egr-1 (Sheng et al. 2002, Zhou et al. 2003, Stambolic et al. 2001). Germline mutations in the 
promoter region of PTEN  resulting in a decrease of the amount and loss of function of the 
PTEN protein have been shown to cause Cowden syndrome in a similar manner to 
inactivating protein coding PTEN mutations (Zhou et al. 2003), (see 2.3.1.2). A cis-acting E-
box element at position -2181 to -2176 from translation start site of the PTEN gene, mediating 
the transcriptional activity, is often deleted in PHTS patients (Pezzolesi et al. 2007). The 
PTEN protein has two major domains, the N-terminal phosphatase domain and the C-terminal 
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domain, which increases protein stability and functions in protein-protein interactions (Lee et 
al. 1999, Georgescu et al. 2000). The expression level of PTEN is also regulated post-
transcriptionally through miRNA binding, which is affected by the expression of a PTENP1 
pseudogene, which, through high level of homology at the 3’UTR region with PTEN, acts as a 
decoy target for miRNAs binding the transcripts (Poliseno et al. 2010). 
 
Figure 2. A diagram of the promoter region of the PTEN gene with known transcription factor binding 
sites and putative transcription start sites. The full promoter region is located from nucleotide -745 
to -1344 and the minimal promoter region from nucleotide -821to -958 from the translation start site. 
Adapted from (Teresi et al. 2007). 
Somatic mutations in the components of the PI3K pathway are among the most frequent 
genetic alterations in cancer (Shaw, Cantley 2006). In breast cancer, activating mutations in 
the PIK3CA gene occur in approximately 25% of the cases (Bachman et al. 2004, Perez-
Tenorio et al. 2007). The expression of PTEN is lost or reduced in 27-50% of breast cancer 
(Depowski et al. 2001, Bose et al. 2002, Lee et al. 2004, Torres et al. 2001, Tsutsui et al. 
2005, Perez-Tenorio et al. 2007)   through mutations or epigenetic mechanisms (Perren et al. 
1999, Khan et al. 2004, Bose et al. 2002). PTEN-related tumor suppression is a dosage-
dependent mechanism in which even a slight decrease of the amount of the protein may affect 
the tumor formation (Carracedo et al. 2011, Berger et al. 2011). In mice a decrease of the 
amount of the PTEN protein to 80% of the normal level increases the susceptibility to cancer, 
and affected the biology and expression profiles of cancer cell proliferation-related genes in 
mammary tissue (Alimonti et al. 2010). The elevated expression of PTEN in mice, however, 
introduced tumor resistance through a metabolic state with tumor suppressive effects (Garcia-
Cao et al. 2012). The reduced amounts of expressed PTEN protein in breast tumors have been 
associated with worse prognosis and aggressive characteristics of the disease (Depowski et al. 
2001, Bose et al. 2002, Tsutsui et al. 2005). Similar effects are also seen in tumors with 
aberrant PI3K/akt pathway (Perez-Tenorio et al. 2007, Lopez-Knowles et al. 2010). Breast 
-745-1344
Exon 1
-837-869-925-972-1031
-821-958
0
Full promoter region Minimal promoter region Sp1 binding site EGR1 binding site
p53 binding site CBF-1 binding siteTranslation start site Putative transcription start site
 24 
 
tumors with aberrant PTEN expression present a gene expression signature which is 
associated with poor prognosis also in prostate and bladder carcinoma (Saal et al. 2007). Loss 
of PTEN expression is also associated with basal-like breast cancer and inactivation of Pten is 
a driver event for the formation of basal-like mammary tumors in mice (Saal et al. 2008). 
Particularly in BRCA1 deficient breast tumors, PTEN expression is often lost through gross 
mutations, such as inversions, deletions, and intragenic chromosome breaks (Saal et al. 2008). 
Germline mutations in the PTEN gene have not been found outside PTHS families (Carroll et 
al. 1999, Guenard et al. 2007) and common variants of the gene have not been associated with 
breast cancer risk (Haiman et al. 2006, Guenard et al. 2007).  
2.7 eIF4E 
One of the major alterations in cancer is aberrant translation of mRNAs (Pandolfi 2004). This 
is one of the mechanisms which oncoproteins can exploit to increase their levels in tumor 
cells. A key regulator of translation is the eIF4F complex, consisting of three subunits: eIF4E, 
eIF4G, and eIF4A. The subunits have specific functions in the complex: eIF4E binds to 
mRNA 5’ cap structures; eIF4A uses its RNA helicase properties to unwind the secondary 
structures of mRNA and make it accessible to the 43S ribosomal subunits; and eIF4G as a 
scaffolding protein binds the subunits together (Gingras et al. 1999).  
The eIF4F complex regulates translation initiation particularly for transcripts which have long 
GC-rich 5’UTR structures, including many oncogenic transcripts, for example VEGF, Cyclin 
D1, and MMP-9. The complex also plays a more general role in translational regulation of 
transcripts with complex 5’ structures (De Benedetti, Graff 2004). A limiting factor to eIF4F 
formation is the availability of free eIF4E, which is normally bound by 4EBP molecules, 
restricting the complex formation. The 4EBPs can be phosphorylated by mTOR, a 
downstream target of the PIK3/AKT pathway, releasing eIF4E to enhance the translation rate 
(Gingras et al. 2001). The gene expression of eIF4E is regulated on the transcriptional level 
by the Myc oncogene through binding to the promoter region (Ruggero 2009). The 
suppression of eIF4E expression decreases the growth rate of tumor cells and induces 
apoptosis in vitro (Dong et al. 2009). The suppression of the eIF4F complex in vivo also 
delayed breast cancer progression and inhibited the translation of VEGF, MMP-9, and Cyclin 
D1 (Nasr et al. 2013). 
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Increased levels of eIF4E have been detected in breast, prostate, bladder, cervical, and lung 
cancer and in head and neck carcinoma (Mamane et al. 2004). In breast cancer its levels have 
been associated with aggressive tumor characteristics and with worse outcome of the disease 
(Byrnes et al. 2006, Coleman et al. 2009, Flowers et al. 2009, Li et al. 1998, Holm et al. 2008, 
McClusky et al. 2005). The prognostic effects of eIF4E have been suggested to be specific to 
patients with tumors presenting the luminal B subtype (Pettersson et al. 2011). The expression 
of eIF4E makes, in a mouse lymphoma model, tumors resistant to doxorubicin and mTOR 
targeting rapamycin treatment with survival effects similar to tumors with activating Akt 
mutations (Wendel et al. 2004). The abnormal translation regulation can also be targeted as a 
therapy in cancer treatment, and eIF4F complex components, particularly the rate limiting 
eIF4E, are among the most promising targets (Malina et al. 2011, Graff et al. 2008). 
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3 Aims of the Study 
1. To study the associations between the PALB2 1592delT Finnish founder mutation and 
breast cancer risk, tumor phenotype and patient survival in Southern Finland with analyses 
also on the tumor phenotype and survival associations of BRCA1 and BRCA2 mutations. 
2. To investigate the role of germline PTEN promoter variation on breast cancer risk, tumor 
phenotype and patient survival. 
3. To evaluate the associations between eIF4E protein expression and characteristics of breast 
tumors as well as patient survival and treatment outcome. 
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4 Materials and Methods 
4.1 Subjects 
4.1.1 Germline DNA samples 
In study I, genotypes of PALB2 mutation 1592delT, and in study II, three PTEN promoter 
polymorphisms were determined from germline DNA samples, isolated from peripheral blood 
lymphocytes, to study their associations with breast cancer risk, tumor characteristics, and 
patient survival in a large set of 1,870 unselected and 542 additional familial breast cancer 
cases and in 1,079 population controls. The unselected series consisted of two cohorts 
collected in Helsinki University Central Hospital’s Department of Oncology in 1997 to 1998 
and in 2000 (Syrjakoski et al. 2000, Kilpivaara et al. 2005) and in the Department of Surgery 
in 2001-2004 (Fagerholm et al. 2008). The first series with 884 patients covered 79%, and the 
second with 986 patients, 87%, of all consecutive newly diagnosed breast cancer cases at the 
time of collection. The additional familial cases were collected at Helsinki University Central 
Hospital’s Department of Clinical Genetics (Vehmanen et al. 1997).  The familial cases were 
further classified as belonging to families with strong familial background, with three or more 
breast or ovarian cancers among first or second degree relatives, including the proband, and to 
families with the proband and one first degree relative affected with breast or ovarian cancer 
(Eerola et al. 2000). 
The familial cases were tested negative for BRCA1 and BRCA2 mutations, with the strong risk 
families screened for variation in the coding regions and exon-intron boundaries of the genes 
using denaturing gradient gel electrophoresis (DGGE) with the large exon 11 of BRCA1 and 
exons 10 and 11 in BRCA2 screened for truncating variation using protein truncation test 
(PTT) and 135 families further for large insertions and deletions using multiplex ligation-
dependent probe amplification (MLPA). The rest of the families were screened for the 
recurrent Finnish BRCA1 and BRCA2 mutations (Vahteristo et al. 2001). In study I, samples 
from 79 BRCA1 mutation carriers from 40 families and 104 BRCA2 mutation carriers from 41 
families were included. The population controls consisted of 1,286 women from matched 
geographical regions obtained through Finnish Red Cross Blood Service. 
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4.1.2 Tumor arrays 
The tissue microarrays (TMA) used in Study III to determine the protein expression of eIF4E 
were constructed from 1,423 paraffin-embedded breast tumors by selecting the most 
representative from hematoxylin and eosin-stained tumor blocks by a breast cancer 
pathologist. A set of four 0.6mm cores from each tumor was transferred to an array block 
(Tommiska et al. 2005). The TMAs had also been used previously to acquire data on 
biomarkers used in the analyses included in this thesis. 
4.1.3 Clinical information and tumor characteristics 
All cancer diagnoses were confirmed through the Finnish cancer registry and hospital records. 
The pathology reports were used for retrieving the data on breast tumor histology and size, 
and for the presence of nodal and distant metastasis at the time of diagnosis (Eerola et al. 
2005). The tumor histology and grade were re-reviewed by a breast cancer pathologist for 
1,423 tumors on the TMAs. The tumors were graded according to the Scarff-Bloom-
Richardson grading system, modified by Elston and Ellis (Elston, Ellis 1991). Information on 
ER and PgR statuses was retrieved from pathology reports (Eerola et al. 2005). Samples with 
more than 10% of the cells stained for ER or PgR by immunohistochemistry (IHC) were 
considered positive. The HER2 status was based primarily on chromogenic in situ 
hybridization (CISH) for the samples on the TMAs with six or more replications considered 
positive and five or less negative. IHC was used when CISH was not available, with samples 
having <10% of the cells stained considered negative and >90% stained positive (Tommiska 
et al. 2008).  
The expression of the p53 protein was assessed on TMAs using IHC and samples with more 
than 20% of the cancer cells stained were considered positive (Tommiska et al. 2005). The 
proliferation marker Ki67 was used to classify the tumors on the TMAs into four categories: 
≥30% of cells stained, strong positive expression (3);  20%-29% of cells stained, intermediate; 
5%-19% of cells stained, weak positive;  and negative with <5% of the cells stained (Ahlin et 
al. 2007). Data on the expression of cytokeratines 5/6, 14, and 17 were used in study I, with 
samples having 0-10% of the cells stained in IHC considered negative and 11%-100% stained 
considered positive (Eerola et al. 2008). Cyclin D1 expression was used in studies I and III 
and Cyclin E in study III, with samples having more positively stained cells with IHC than the 
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mean of the cells stained in all tumors (9.1% for Cyclin D1 and 6.8% for Cyclin E) 
considered positive (Aaltonen et al. 2008).  
The tumors were divided into subtypes according to their ER, PgR, and HER2 status with ER 
or PgR positive, HER2 negative denoted as “ER/PgR+HER2-”, ER or PgR positive, HER2 
positive denoted as “ER/PgR+HER2+”, ER and PgR negative, HER2 positive denoted as 
“ER&Pgr-HER2+”, and ER, PgR, and HER2 negative denoted as “triple negative”. In study I 
a basal-like subgroup was also derived from triple negatives according to the expression of 
basal cytokratines 5/6, 14, or 17. 
The follow-up information for the vital status of the breast cancer patients was obtained from 
the Finnish Cancer Registry and from hospital records. The follow-up information on distant 
metastasis (II) was retrieved from hospital records. The survival was calculated as time 
between the primary surgery and end of follow-up or breast cancer death within 10 years, and 
in study II also between the primary surgery and end of follow-up or breast cancer death or 
distant metastasis (BDDM) within five years from diagnosis. In study I, 2,342 patients with 
invasive breast cancer were included in the survival analysis with a median follow-up time of 
75 months and 284 patients dying of breast cancer within 10 years. In study II, 2,204 patients 
were included with a median follow-up time of 83 months for 10 year breast cancer-specific 
death with 298 events and 47 months for BDDM with 352 events. In study III, 1,028 tumors 
were included in the 10 year breast cancer-specific death analysis with a median follow-up 
time of 100 months and with 175 events. 
4.1.4 Fresh-frozen tumor samples 
In study II, 183 fresh frozen breast tumors were used for gene expression microarray analyses. 
Of the tumors, 151 belong to the patients in the unselected series and 52 to the additional 
familial cases. The total RNA was extracted from the tumor samples using mirVANA RNA 
isolation kit (Life Technologies, Carlsbad, CA, USA). The samples were hybridized to 
Illumina Human HT-12 v3 Expression Bead Chips (Illumina Inc, San Diego, CA, USA). The 
data acquired in this study was submitted to the Gene Expression Omnibus (GEO) database 
(Edgar et al. 2002) according to the MIAME protocol (Brazma et al. 2001) (GSE24450). 
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4.2 DNA analysis methods 
In study I, the PALB2 Finnish founder mutation 1592delT was genotyped in germline DNA 
samples using AmpliFluor fluorescent genotyping (KBiosciences, Cambridge, UK) or with 
conformation sensitive gel electrophosresis (CSGE) heteroduplex analysis (Ganguly 2002). In 
CSGE PCR-amplified DNA fragments are first denaturated for 10 minutes in 95°C and then 
cooled down to room temperature slowly. This creates heteroduplexes between the DNA 
strands with mismatches, which have a distinct mobility patterns in a gel compared to 
homoduplexes. The heteroduplex samples were run in 10% acrylamide, 10% ethylene glycol, 
and 15% formamide mildly denaturing gels with 2W overnight or 30W for 4 hours and 
visualized with silver staining. 
In study II, the promoter region of the PTEN gene was screened for variation in 330 patients 
using CSGE. The detected variants were further genotyped in the whole sample set using 
CSGE for two of the variants (-903GA and -975GC) and Sequenom i-PLEX (Sequenom, San 
Diego, CA, USA) for -1026CA with service provided by FIMM (Institute for Molecular 
Medicine Finland) Genomics services (www.fimm.fi). 
All variants detected with CSGE in studies I and II were verified with direct sequencing. The 
PCR products were first purified using ExoSAP-IT treatment (Affymetrix, Santa Clara, CA, 
USA) and then sequenced with ABI BigDyeTerminator 3.1 Cycle sequencing kit (Life 
Technologies). The sequencing reactions were analyzed either by using the service provided 
by FIMM Sequencing services with ABI3730xl DNA Analyzer (Life Technologies) or by 
running them after acetate ethanol precipitation in AB Prism 310 Genetic Analyzer automated 
sequencer (Life Technologies). 
4.3 Immunohistochemical methods 
The expression of the eIF4E protein in study III was evaluated using IHC. The TMA slides 
were deparaffinizated and hybridized with eIF4E rabbit monoclonal antibody (Cell Signalling 
Technology, #2067, Danvers, MA, USA) diluted 1:400 and stained using an automated 
Ventana Benchmark immunostaining device (Ventana Medical Systems, Oro Valley, AZ, 
USA). The IHC staining intensity was scored semi-quantitatively (low, intermediate, and 
high) two times by two researchers (T.K. and O.C.). All four cores of each tumor sample on 
TMA were scored individually and in the cases where the result varied the most frequent 
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scores were used. Unsuccessfully stained samples and samples with no tumor cells were 
excluded. 
4.4 Statistical methods and bioinformatics 
4.4.1 Associations with risk and tumor characteristics 
The risk analyses and the association analyses between tumor characteristics and genotypes in 
studies I and II and with protein expression in study III were performed using SPSS 15.0 
software (SPSS Inc, Chicago, IL, USA). Pearson’s Χ2 test or Fisher’s exact test, when the 
number in any of the cells was less than five, was used to calculate the P-values. In study III 
linear-by-linear association Χ2 was used for ordinal and binary variables. The associations 
with PALB2, BRCA1, and BRCA2 mutations and the age of onset of breast cancer were 
assessed with student’s t-test. All P-values are two sided. 
4.4.2 Survival analyses 
In studies I and II, the survival analyses were performed using SPSS 15.0. Univariate analyses 
were calculated with logrank test and visualized with Kaplan-Meier plots. Hazard ratios were 
calculated with Cox’s regression. To test the independence of the variables from the common 
prognostic factors (tumor size (T), nodal status (N), metastasis at diagnosis (M), ER, PgR, 
HER2, p53, Ki67, and grade) multivariate models were constructed, with a forward 
conditional algorithm in study I and a backward conditional in study II. In study II, the three 
promoter variants were combined in multivariate analysis as a single variable to increase the 
statistical power. 
In study III, the survival analyses were performed with the R environment (www.r-
project.org) Survival package (Therneau 2002). The survival times were left-truncated for the 
time of entry to the study in prevalent cases. Univariate effects of the eIF4E expression were 
evaluated with Kaplan-Meier analyses with logrank test. The multivariate model was adjusted 
for tumor size, nodal status, metastasis at diagnosis, ER, PgR, grade, and age of diagnosis. 
The tumor characteristics (ER, PgR, HER2, Nodal status, grade, p53, Ki67) and treatment 
(chemotherapy, anthracycline, CMF, and endocrine treatment) were further used to stratify 
the survival analyses into mutually exclusive subgroups which were tested for heterogeneity 
with two-sample z-tests on the coefficients (log(HR)) of corresponding univariate Cox 
models. 
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4.4.3 Gene expression microarray analyses 
In study II, the raw data was imported into the R environment and analyzed using 
BioConductor packages (Gentleman et al. 2004) with quality control (Du et al. 2008) and 
normalization by the quantile method (Bolstad et al. 2003). The primary breast tumors of ten 
PTEN promoter variant carriers and 10 non-carriers matched with ER, PgR, HER2, Grade 
tumor size, p53 and Ki67 were compared for gene expression matrix for the average of probes 
matching the same Entrez gene IDs and the differential expression was evaluated by 
moderated t-test, with P < 0.01 considered significant (Smyth 2005). The differentially 
expressed genes were functionally annotated using DAVID functional annotation tools 
(Huang da et al. 2009) with categories having Fisher’s exact P-value < 0.05 considered as 
significant enrichment. 
The 160 genes differentially expressed between the tumors of PTEN promoter variant carriers 
and matched non-carriers were used to cluster the set of 183 tumors (GSE24450) into two 
groups with unsupervised clustering based on the overall expression of the signature genes 
(Lukes et al. 2009) and analyzed for breast cancer survival or occurrence of distant metastasis 
within five years from diagnosis with Kaplan-Meier analysis and Log-Rank test. A pre-
defined random number selection algorithm was imposed at the beginning of the process to 
stabilize the results with 100,000 iterations of the K-means algorithm. Unsupervised 
clustering was further applied to divide three additional independent breast cancer datasets 
retrieved from GEO database (GSE1456 from Stocholm (Pawitan et al. 2005), GSE2034 from 
Rotterdam (Wang et al. 2005), and GSE4922 from Uppsala (Ivshina et al. 2006)) into two 
categories for the validation of the survival effects of the signature genes. 
4.5 Ethical aspects 
All studies were performed with informed consent from the patients and permissions from the 
ethics committee of the Helsinki University Central hospital and the Ministry of Social 
Affairs and Health in Finland.  
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5 Results 
5.1 PALB2 1592delT 
5.1.1 Breast cancer risk 
The PALB2 1592delT allele was present in altogether 12 (0.7%) of the 1,706 unselected 
patients, 19 (2.0%) of the 947 familial cases, and 2 (0.2%) of the 1,079 population controls 
genotyped (I, Table 1), indicating a trend of increased risk with mutation carriers with 
increasing family history of breast cancer (Figure 3). The mutation was also found in two 
unrelated BRCA2 mutation carriers (with c.8947dupG, p.Asp2983fs and c.7480C>T, 
p.Arg2494X mutations) of the 104 screened, but not in any of the 79 BRCA1 mutation carriers 
tested. 
 
Figure 3. OR of PALB2 1592delT in patients with increasing familial burden of breast cancer with 
familial with three or more affected OR = 14.27 (95% CI 3.09-132.82, P = 3.69x10
-5
), familial with 
two affected OR = 8.40 (95% CI 1.67-81.34, P = 0.0028), and in sporadic OR = 3.40 (95% CI 0.68-
32.97, P = 0.1207). 
The mean age of onset of breast cancer of the carriers of the PALB2 1592delT mutation was 
53.1 years (33.4–79.9 years), not significantly different from that of familial (54.8. years P = 
0.472) or sporadic (58.0 years P = 0.152) breast cancer patients. In BRCA1 and BRCA2 
carriers, the age of onset was, however, significantly lower than in non-carriers, at 45.2 years 
and 47.4 years, respectively (P < 0.001). Contralateral breast cancer was present at a similar 
frequency in PALB2 mutation carriers and other familial cases, with 3 of 28 (10.7%) PALB2 
carriers having contralateral breast cancer compared to the frequency of 10.9% in the familial 
cases (P = 0.99). 
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5.1.2 Tumor features 
The PALB2 mutation was associated with numerous tumor properties of aggressive breast 
cancer. These tumors were more frequently of a higher grade, had higher expression of the 
Ki67 proliferation marker, and were more often ER and PgR negative (Table 2).  All but one 
tumor of 22 PALB2 mutation carriers (4.5%) with HER2 data were negative for HER2 
overexpression/amplification, but the difference was not statistically significant when 
compared to familial or sporadic cases. The PALB2 mutation status also associated strongly 
with the clinically challenging triple negative phenotype. The expression of cytokeratines 
alone was associated with the PALB2 mutation only for cytokeratine 14 when compared to 
sporadic cases, although the overall trend of cytokeratine expression seemed to be more 
frequently high in the tumors of PALB2 mutation carriers. The basal-like subtype separated 
from the triple negatives by cytokeratine expression was also more frequent in PALB2-related 
tumors compared to the tumors of non-carriers (OR = 8.29, 95% CI 3.26-21.03, 
P = 1.388x10
-7
). The expression of Cyclin D1 and Cyclin E was more often low in PALB2 
carriers. 
To compare the tumor phenotype of PALB2 mutation carriers to BRCA1 and BRCA2 carriers, 
the analyses were also performed on the mutation carriers of those genes (I, supplementary 
Table 1). The tumors of BRCA1 carriers were even more frequently negative for ER (74.6%) 
and PgR (80.6%) than PALB2 mutation carriers but had less often lymph node metastasis at 
diagnosis (28.2%). Similar to the tumors of PALB2 mutation carriers, the BRCA1 and BRCA2 
mutation carriers very rarely had HER2 positive tumors, with only one BRCA1 carrier (2.4%) 
having a HER2 positive breast cancer. The BRCA1-related tumors were also more often triple 
negative (70.0%) and basal-like (27.5%) compared to the tumors of familial or sporadic 
patients, but the tumors of BRCA2 carriers were more frequently of the ER/PgR+HER- 
subtype (77.3%) (Figure 4 C). With tumor grade and Ki67 expression, PALB2 tumors seem to 
lie between BRCA1 and BRCA2-related tumors (Figure 4 A and B). 
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Table 2. Comparison of tumor characteristics of PALB2 1592delT mutation carriers and non-carriers 
(WT). 
Category 
PALB2 
1592delT % WT % P-value OR 95% CI 
T 
       1 20 (60.6%) 1375 (61.3%) 0.9325 0.97 0.48-1.96 
2, 3 & 4 13 (39.4%) 867 (38.7%) 
   N 
    
   negative 15 (45.5%) 1248 (55.9%) 0.2286 0.66 0.33-1.31 
positive 18 (54.5%) 983 (44.1%) 
   M 
    
   negative 32 (97.0%) 2180 (96.6%) > 0.9999 1.13 0.15-8.38 
positive 1 (3.0%) 77 (3.4%) 
   ER 
    
   negative 14 (46.7%) 398 (18.5%) 0.0001 3.86 1.87-7.98 
positive 16 (53.3%) 1757 (81.5%) 
   PR 
    
   negative 17 (56.7%) 733 (34.0%) 0.0096 2.53 1.22-5.24 
positive 13 (43.3%) 1420 (66.0%) 
   HER2 
    
   negative 21 (95.5%) 1070 (84.9%) 0.2328 3.73 0.50-27.89 
positive 1 (4.5%) 190 (15.1%) 
   p53 
    
   negative 18 (78.3%) 976 (79.7%) 0.8676 0.92 0.34-2.50 
positive 5 (21.7%) 249 (20.3%) 
   grade 
    
   1 3 (9.4%) 574 (26.7%) 0.0018 0.34 0.17-0.69 
2 12 (37.5%) 972 (45.2%) 1 and 2 vs 3 
  3 17 (53.1%) 604 (28.1%) 
   tumor histology 
    
   ca ductale 25 (75.8%) 1526 (67.3%) 0.3041 1.52 0.68-3.38 
ca lobulare 3 (9.1%) 481 (21.2%) Ductal vs other 
 ca medullare 0 (0.0%) 28 (1.2%) 
   other 5 (1.,2%) 232 (10.2%) 
   Type 
 
 
 
 
   ER/PgR+HER2- 9 (40.9%) 900 (73.8%) 2.217x10
-10
 9.88 4.19-23.32 
ER/PgR+HER2+ 1 (4.5%) 118 (9.7%) Triple-neg vs other 
 ER&PgR-HER2+ 0 (0.0%) 69 (5.7%) 
   TripleNeg 12 (54.5%) 132 (10.8%) 
   Ki67 
    
   0 3 (10.3%) 430 (21.5%) 0.0023 0.32 0.15-0.69 
1 7 (24.1%) 814 (40.7%) 0 and 1 vs 2 and 3 
 2 8 (27.6%) 373 (18.7%) 
   3 11 (37.9%) 382 (19.1%) 
   Cyclin E 
   
 
   High 9 (40.9%) 163 (16.9%) 0.0034 3.40 1.43-8.08 
Low 13 (59.1%) 800 (83.1%) 
   Cyclin D1 
   
 
   High 7 (31.8%) 511 (52.8%) 0.0509 0.42 0.17-1.03 
Low 15 (68.2%) 456 (47.2%) 
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Figure 4. The subtype (A), grade (B), and Ki67 (C) distribution, in the familial, sporadic, 
PALB2, BRCA1, and BRCA2-related breast cancer. 
 
5.1.3 Survival 
The association between survival and the PALB2 mutation was analyzed together with 
BRCA1 and BRCA2 mutations and compared with familial and sporadic patients. As familial 
and sporadic cases did not show differences in survival, the groups were combined in the 
analyses when compared to mutation carriers. The PALB2 mutation carriers had a survival 
effect (HR = 1.61, 95% CI 0-71-3.61, P = 0.2524) similar to BRCA1 carriers (HR = 1.67, 95% 
CI 0.99-2.82, P = 0.0546) in the primary analysis, but neither of the effects were significant 
(I, Table 3). BRCA2 mutation carriers, however, had a strongly increased risk of death of 
breast cancer in the long-term 10 year analysis (HR = 2.34, 95% CI 1.50-3.66, P = 0.0002), 
with the survival difference becoming noticeable only after five years of follow-up (I, Figure 
1 A). 
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As the HER negative tumors were a major subgroup among the mutation carriers of all three 
genes, the survival analyses were stratified, with HER2 status producing a similar survival 
pattern between BRCA2 (HR = 3.75, 95% CI 2.18-6.45, P = 1.781x10
-6
) and PALB2 (HR = 
2.94, 95% CI 1.29-6.69, P = 0.0104) mutation carriers (I, Figure 1 B). BRCA1 carriers, 
however, did not have a survival effect that was different from non-carriers in this subgroup 
(P = 0.3592). The association of the PALB2 mutation with survival was further analyzed in 
familial cases only, among which it had a significant association with prognosis (HR = 2.30, 
95% CI 1.01-5.24, P = 0.0466) (I, Figure 1 C), and also in familial HER2 negative cases 
where the strongest survival effect for PALB2 mutation was seen (HR = 4.57, 95% CI 1.96-
10.64, P = 0.0004) (I Figure 1 D). 
In the multivariate analysis adjusted for common prognostic factors (I, Table 4), carrying a 
BRCA2 mutation was a strong independent prognostic factor, together with grade, T, N, M, 
PgR, and HER2, in the final step of the Cox’s regression model increasing the risk of dying of 
breast cancer by two-fold within the 10 years from diagnosis in all cases (P = 0.0418) and in 
HER2 negative cases, together with T, N, M, PgR, and p53, (P = 0.0459). Carrying a PALB2 
mutation was an independent prognostic factor in HER2 negative cases, together with T, N, 
M, PgR, and p53, with 2.5-fold risk (P = 0.0399), in familial cases, together with T, N, M, 
and ER, with 2.4-fold risk (P = 0.0505), and with familial HER2 negative cases, together with 
T, N, M, and ER, with 3.5-fold risk (P = 0.0082) of dying of breast cancer within the follow-
up time. 
5.2 PTEN promoter variants 
5.2.1 Detection and breast cancer risk 
Three variants were detected when the promoter region of the PTEN gene was screened using 
CSGE in a set of 330 breast cancer patients with strong family history of breast or breast and 
ovarian cancer. Two of the variants, -1026CA (rs34149102) and -903GA (rs1044322), were 
previously known low-frequency polymorphisms, and one, -975GC, a novel variant, with the 
number representing the distance from the translation start-site.  
In the genotyping of the complete dataset the variants were present with frequencies of 2% 
for -1026CA, 1% for -975GC, and 3% for -903GA. Two patients had both -1026CA 
and -903GA and one patient both -903GA and -975GC variants. The promoter variants did 
not associate with breast cancer risk when compared to population controls in unselected or 
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familial cases, although a very low increase in risk cannot be excluded (Table 3) (Heikkinen 
et al., unpublished results). 
5.2.2 Tumor features 
The -975GC variant was associated with distant metastasis at diagnosis (OR = 4.99, 95% CI 
1.69-14.78, P = 0.013) and -1026GA with high expression of Ki67 (OR = 2.21, 95% CI 1.15-
4.28, P = 0.015) when compared to the tumors of non-carriers (II, Table S1). No other 
significant associations were detected with the promoter variants and tumor characteristics 
tested (tumor size, nodal status, grade, histology, ER, PgR, HER2, and p53). 
Table 3. Frequencies of the three PTEN promoter variants and of carriers of any of the variants in 
breast cancer cases and controls compared to non-carriers (Heikkinen et al., unpublished results). 
PTEN -903GA Total GG (%) GA (%) p-value OR 95% CI 
Population controls 1272 1241 (97.6) 31 (2.4)       
Familial, two affected 522 506 (96.9) 16 (3.1) 0.449 1.27 (0.69-2.33) 
Familial, three or more affected 429 416 (97.0) 13 (3.0) 0.503 1.25 (0.65-2.41) 
All familial breast cancer cases 951 922 (97.0) 29 (3.0) 0.378 1.26 (0.75-2.10) 
Unselected breast cancer patients 1709 1662 (97.2) 47 (2.8) 0.596 1.13 (0.72-1.79) 
Sporadic breast cancer patients 1286 1253 (97.4) 33 (2.6) 0.835 1.05 (0.64-1.73) 
         
         PTEN -975GC Total GG (%) GC (%) p-value OR 95% CI 
Population controls 1272 1258 (98.9) 14 (1.1)       
Familial, two affected 522 516 (98.9) 6 (1.1) 0.929 1.04 (0.40-2.73) 
Familial, three or more affected 429 422 (98.4) 7 (1.6) 0.389 1.49 (0.60-3.72) 
All familial breast cancer cases 951 938 (98.6) 13 (1.4) 0.571 1.25 (0.58-2.66) 
Unselected breast cancer patients 1709 1692 (99.0) 17 (1.0) 0.778 0.90 (0.44-1.84) 
Sporadic breast cancer patients 1286 1270 (98.8) 16 (1.2) 0.736 1.13 (0.55-2.33) 
         
         PTEN -1026CA Total CC (%) CA (%) p-value OR 95% CI 
Population controls 1260 1244 (98.7) 16 (1.3)       
Familial, two affected 523 515 (98.5) 8 (1.5) 0.665 1.21 (0.51-2.84) 
Familial, three or more affected 423 415 (98.1) 8 (1.9) 0.351 1.50 (0.64-3.53) 
All familial breast cancer cases 946 930 (98.3) 16 (1.7) 0.413 1.34 (0.67-2.69) 
Unselected breast cancer patients 1719 1685 (98.0) 34 (2.0) 0.137 1.57 (0.86-2.85) 
Sporadic breast cancer patients 1294 1268 (98.0) 26 (2.0) 0.142 1.59 (0.85-2.99) 
         
         PTEN promoter variant Total wt (%) variant (%) p-value OR 95% CI 
Population controls 1252 1191 (95.1) 61 (4.9)       
Familial, two affected 520 491 (94.4) 29 (5.6) 0.538 1.15 (0.73-1.82) 
Familial, three or more affected 423 396 (93.6) 27 (6.4) 0.229 1.33 (0.83-2.12) 
All familial breast cancer cases 943 887 (94.1) 56 (5.9) 0.271 1.23 (0.85-1.79) 
Unselected breast cancer patients 1700 1604 (94.4) 96 (5.6) 0.354 1.17 (0.84-1.62) 
Sporadic breast cancer patients 1278 1204 (94.2) 74 (5.8) 0.304 1.20 (0.85-1.70) 
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5.2.3 Survival 
All three PTEN promoter variants associated with decreased breast cancer specific survival in 
the 10 year analyses with P = 0.016 for -903GA, P = 0.002 for -975GC, and P = 0.014 
for -1026CA (II, Figure 1 A). The variants -903GA and -975GC also associated with five year 
breast cancer death or distant metastasis-free survival with P = 0.002 and P = 0.010, 
respectively (II, Figure 1 B). In Cox’s regression analysis, carrying any of the variants 
approximately doubled the risk of dying of breast cancer within 10 years (HR = 2.17, 95% CI 
1.52-3.10, P = 0.00002) or developing metastasis, or dying of breast cancer in five years from 
diagnosis (HR = 1.97, 95% CI 1.40-2.79, P = 0.00011) (II, Table 1), with the effects 
visualized in Figure 5 with Logrank P-values. In the multivariate analyses, carrying any of the 
promoter variants was an independent prognostic factor when adjusted by the established 
prognostic markers in the final step of the Cox’s regression, together with T, N, M, grade, and 
PgR in 10 year breast cancer specific analysis (P = 0.0119) and in five year breast cancer 
death or distant metastasis-free analysis, together with T, N, grade, and PgR (P = 0.0381) (II, 
Table 2). 
 
Figure 5. Kaplan-Meier plots of cumulative survival for carrying any of the three PTEN promoter 
variants (grey) compared to wild type (black) for ten year breast cancer death specific survival (A) 
(P = 1.088x10
-5
) and for five year breast cancer death or distant metastasis free survival (B) 
(P = 1.974x10
-4
). 
 
A B
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5.2.4 Gene expression signature 
The microarray analysis of the tumor samples of 10 PTEN promoter variant carriers and 10 
matched non-carriers revealed a signature of 160 differentially expressed genes (II, Table S2), 
with P < 0.01, although none of them remained significant after post hoc correction. In the 
tumors of the promoter variant carriers, 56 if the genes showed decreased, and 104 increased, 
expression levels, with changes spanning between 1.81 and -1.85 base 2 log fold (3.5/-3.6 in 
natural scale). Clustering of the subjects with the expression profiles of the 160 genes co-
segregated within branches of hierarchical clustering (II, Figure 2). No segregation was 
present when the complete expression matrix of 24,660 genes was used in hierarchical 
clustering. No differences in the mRNA levels of the PTEN gene was detected between the 
tumors of the promoter variant carriers and non-carriers. 
The annotation of the differentially expressed genes linked the genes with increased 
expression in the tumors of the PTEN promoter variant carriers to ATP-binding, protein 
phosphorylation, and protein kinases. In down-regulated genes, DNA-binding and 
transcription factor proteins were over-represented functional groups (II, Table S3). When 
compared to 150 genes in the expression signature of somatic PTEN deficiency in breast 
tumors (Saal et al. 2007) only one, TUBB2C, was shared with the signature identified here. 
On the functional level, the signatures, however, shared biological themes such as 
phosphoprotein and ATP-binding in up-regulated genes and DNA-binding and transcription 
regulation in down-regulated genes. 
The gene expression dataset of 183 breast tumors and three independent publically available 
datasets were used to evaluate the effect of the gene signature on breast cancer survival. 
Unsupervised clustering of the signature genes divided the sample sets into two groups with 
significant association with survival in the Helsinki, Stockholm, and Rotterdam datasets (II, 
Figure 3). When the clustering was done using the gene expression signature of somatic 
PTEN loss (Saal et al. 2007), a significant survival effect was seen in all four data sets 
(Helsinki P = 1.06x10
-6
, Stockholm P = 0.003, Rotterdam P = 0.001, and Uppsala P = 0.002). 
The Saal signature and the PTEN promoter variant signature described in this study clustered 
93%, 74%, 69%, and 76% of the tumors in corresponding survival groups in the Helsinki, 
Stockholm, Rotterdam, and Uppsala datasets, respectively. 
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5.3 eIF4E protein expression 
5.3.1 Tumor features 
Of the 1,085 successfully stained tumors, 102 showed high, 518 moderate, and 465 low eIF4E 
IHC staining (III, Figure 1). Increasing eIF4E protein expression associated with higher 
tumor grade, larger tumor size, ER and PgR negativity, p53 positivity, and higher levels of 
Ki67, Cyclin E, and Cyclin D1. The breast tumors with high eIF4E IHC were also more often 
medullary for histological type than tumors with low or intermediate expression (OR = 6.28, 
95% CI 2.02-79.58, P = 0.0003) (III, Table 1). High eIF4E, furthermore, associated with 
higher frequency of triple negative (OR = 2.45, 95% CI 1.50-3.99, P = 0.0002), 
ER/PgR+HER2+ (OR = 2.41, 95% CI 1.35-4.29, P = 0.0021), or ER&PgR-HER2+ 
(OR = 3.29, 95% CI 1.65-6.57, P = 0.0004) tumor subtype, and were less often of 
ER/PgR+HER2- subtype. The eIF4E expression did not associate with family history of 
breast cancer when comparing the tumors of familial and sporadic patients with high and 
intermediate or low eIF4E (P = 0.3030). 
5.3.2 Survival 
High expression of eIF4E was associated with worse breast cancer death specific survival in 
the 10 year analysis when compared to low or intermediate eIF4E expressing tumors (HR = 
1.99, 95% CI 1.32-3.00, P = 0.0008) (III, Figure 3 A). There was no difference in the survival 
of the patients with tumors with low or intermediate eIF4E expression (HR = 0.97, 95% CI 
0.71-1.35, P = 0.8779) and therefore the two groups were combined for the analyses. High 
eIF4E was also an independent prognostic factor in multivariate analysis adjusted for T, N, 
M, grade, ER, and age of diagnosis (P = 0.0400) (III, Table 2). 
In subgroup analyses, the dataset was stratified by ER, PgR, HER2, Nodal status, grade, p53, 
and Ki67, as well as by chemotherapy and endocrine treatment (III, Table 3). From the 
treatment subgroups, the strongest hazard was seen in the subgroup of patients treated with 
anthracycline-based chemotherapy (HR = 3.34, 95% CI 1.72-6.48, P = 0.0002). In patients 
not receiving chemotherapy or patients treated with CMF no differential survival effect was 
observed.  The difference of the survival effects in the subgroup of patients treated with 
anthracycline was also significant in heterogeneity analysis compared to patients not treated 
with anthracycline (P = 0.0358) or who had not received any chemotherapy (P = 0.0481). The 
survival associations were consistent in subgroups of different tumor characteristics, with 
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high eIF4E being associated with worse survival. The survival effect was strongest in the 
subgroup of nodal positive patients (HR = 2.68, 95% CI 1.68-4.29, P = 1.76x10
-5
). There was 
no significant difference in heterogeneity in the tumor characteristic subgroups. High eIF4E 
expression associated also with survival in metastasized breast cancer (HR = 1.88, 95% CI 
1.20-2.94, P = 0.0060) in the five year analysis after detection of distant metastasis compared 
to low or intermediate expression. 
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6 Discussion 
6.1 PALB2 
The Finnish PALB2 founder mutation was identified in 2.0% of familial and 0.7% of 
unselected breast cancer patients and in 0.2% of population controls. The frequencies seen 
here are in line with previous studies of the mutation in breast cancer patients from Northern 
Finland (Erkko et al. 2007). The increase in risk of breast cancer caused by PALB2 mutations 
remains to be clarified, but it seems to be higher (Erkko et al. 2008, Casadei et al. 2011, 
Tischkowitz et al. 2012) than the approximately two-fold increase first reported (Rahman et 
al. 2007). The results here show a trend of increasing frequency of the mutation with 
increasing family history, consistently with a multiplicative model of hereditary breast cancer 
predisposition, which might also have affected the high risk estimates reported for PALB2-
related breast cancer risk in family based segregation analysis (Erkko et al. 2008, 
Tischkowitz, Xia 2010). In the multiplicative model, a number of yet unknown susceptibility 
alleles enriched in families may act together with the known mutations to form the overall 
risk, as has been proposed also for the CHEK2 1100delC moderate-penetrance variant 
(CHEK2 Breast Cancer Case-Control Consortium 2004). The considerable increased risk in 
mutation carrying families supports the potential for genetic testing of PALB2 1592delT in the 
clinical management of breast cancer families in Finland. As this study focused only on the 
relatively frequent founder mutation and previous studies have analyzed only 113 breast 
cancer families from northern Finland for variation in the whole coding region of the gene 
(Erkko et al. 2007), it is possible that also other rare PALB2 mutations are present among 
Finnish breast cancer families, likely with similar frequencies as seen in other populations. 
Two PALB2 carriers also harbored mutations in the BRCA2 gene. Such double mutations have 
not been identified elsewhere, although one case with both PALB2 and BRCA1 mutations has 
been reported (Pern et al. 2012). These patients did not show any particularly striking 
phenotype, and the potential effects of double mutations require further investigations. They 
were diagnosed with breast cancer at the ages of 38 and 46 years, which is slightly younger 
than the mean age of diagnosis of BRCA2 mutation carriers of 47 years. No conclusion can be 
made from the segregation of the variants in these families due to the lack of samples from 
the family members. 
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The tumor phenotype of PALB2 mutation carriers has been reported with a relatively small 
number of tumors in separate datasets with incomplete conclusions, and has mostly had 
limited clinical information (Tischkowitz, Xia 2010). The 33 tumors of PALB2 mutation 
carriers in this study account for 29% of all PALB2 carrier breast tumors published so far and 
an even larger proportion of tumors with information available on clinically relevant tumor 
characteristics. The comparison of tumor characteristics reported in different studies is 
challenging as methods and protocols vary between publications. Here, the PALB2-related 
tumors presented properties of aggressive disease with high grade and proliferation status, and 
were frequently triple negative for ER, PgR, and HER2. These features are largely shared 
with other studies (Table 4) when the invasive breast tumors described in 14 studies on 
carriers of 23 different truncating PALB2 mutations are combined and the numbers compared 
to those of the PALB2-related tumors described in this study.  Triple negative tumors, 
however, are clearly less frequent with borderline significant P-values among the PALB2 
mutation carriers in other studies, and ER, PgR, and HER2 negativity is also in general more 
frequent in our study. Different mutations may have different effects on tumor phenotype and, 
indeed, none of the other seven tumors of 1592delT mutation carriers described so far showed 
high expression of HER2 (Erkko et al. 2007). Other variants present in distinct populations 
may also affect the tumor properties individually or by modifying the effect of a PALB2 
mutation. The collection of the patient material may also be biased and affect the comparison 
of the studies. 
As PALB2 and BRCA2 function very closely together, it could have been presumed that their 
germline loss would result in similar tumor phenotypes. This, however, was not the case here, 
as the tumors of PALB2 carriers resembled more closely those of BRCA1 mutation carriers in 
many properties. For example both PALB2 and BRCA1 tumors were frequently triple 
negative, whereas BRCA2-related tumors were more often Luminal, as has been previously 
reported (Sorlie et al. 2003, Melchor et al. 2008). Whether other alleles also affect the 
characteristics of the tumors of PALB2 mutation carriers remains to be investigated. This 
would likely require much larger data sets due to the low frequency of the mutations. 
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Table 4. The frequencies of PALB2-related tumors published (Erkko et al. 2007, Foulkes et al. 2007, 
Tischkowitz et al. 2007, Garcia et al. 2008, Cao et al. 2008, Sluiter et al. 2009, Papi et al. 2010, Balia 
et al. 2010, Dansonka-Mieszkowska et al. 2010, Hellebrand et al. 2011, Bogdanova et al. 2011, Pern et 
al. 2012, Teo et al. 2013a, Teo et al. 2013b) compared to the tumors of PALB2 mutation carriers and 
non-carriers, wild type (WT), from this study. P-values are calculated for the difference between 
PALB2 carriers of this study compared to other studies. 
 
PALB2 
 
PALB2 
 
WT 
  
Category 
Other 
studies % 
This 
Study % 
This 
Study % P-value 
Tumor histology 
       ca ductale 53 (82.8%) 25 (75.8%) 1526 (67.3%) 0.4068 
ca lobulare 8 (12.5%) 3 (9.1%) 481 (21.2%) ductal vs other 
ca medullare 1 (1.6%) 0 (0.0%) 28 (1.2%) 
 other 2 (3.1%) 5 (15.2%) 232 (10.2%) 
 Grade 
       1 3 (6.5%) 3 (9.4%) 574 (26.7%) 0.7859 
2 20 (43.5%) 12 (37.5%) 972 (45.2%) 1 and 2 vs 3 
3 23 (50.0%) 17 (53.1%) 604 (28.1%) 
 ER 
       positive 44 (67.7%) 16 (53.3%) 1757 (81.5%) 0.1775 
negative 21 (32.3%) 14 (46.7%) 398 (18.5%) 
 PgR 
       positive 29 (49.2%) 13 (43.3%) 1420 (66.0%) 0.6032 
negative 30 (50.8%) 17 (56.7%) 733 (34.0%) 
 HER2 
       postive 8 (21.6%) 1 (4.3%) 190 (15.1%) 0.1337 
negative 29 (78.4%) 21 (95.5%) 1070 (84.9%) 
 Subtype 
       ER/PgR+/HER2- 17 (48.6%) 9 (40.9%) 900 (73.8%) 0.0499 
ER/PgR+HER2+ 7 (20.0%) 1 (4.5%) 118 (9.7%) TripleNeg vs 
ER&PgR-HER2+ 1 (2.9%) 0 (0.0%) 69 (5.7%) other 
TripleNeg 10 (28.6%) 12 (54.5%) 132 (10.8%) 
 
The PALB2 mutation also affected the long-term prognosis of breast cancer patients in 
familial cases and among patients with HER2 negative tumors. This association was similar to 
that of patients with a BRCA2 mutation, which was also found to be an independent 
prognostic factor in the multivariate analysis. The survival effects related to the mutations of 
both of these genes became noticeable only after five years of follow-up. Previous studies 
have mostly focused on shorter-term survival, which might explain why BRCA2-related 
survival effects have not been as strong as the effects described here. Recently, however, the 
effects of BRCA2 mutations on breast cancer prognosis have, consistently with our results, 
been clarified and the mutations indeed seem to associate with worse survival in long-term 
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follow-up analysis (Goodwin et al. 2012). BRCA1 mutations did not associate with long-term 
survival of breast cancer patients, but in the Kaplan-Meier plots, a slight differentiation in the 
survival rate can be seen at an early state of the follow-up, although this effect was not 
statistically significant. It remains unlikely that BRCA1 mutations would play major impact 
on breast cancer prognosis (Rennert et al. 2007, Bordeleau et al. 2010, Goodwin et al. 2012). 
6.2 PTEN promoter variants 
In the screening of the promoter region of the PTEN gene, three low-frequency 
variants, -903GA, -975GC, and -1026CA, were identified. None of the variants associated 
with breast cancer risk, although very low risk effects cannot be excluded. The PTEN 
promoter variants associated with the prognosis of breast cancer patients. The -975GC variant 
also associated with metastasis at diagnosis and -1026CA with higher level of Ki67 
proliferation marker. In multivariate survival analysis, carrying a PTEN promoter variant 
approximately doubled the risk of death due breast cancer within 10 years, or developing a 
distant metastasis or dying of breast cancer within five years from diagnosis. These findings 
indicate that the PTEN promoter variants may have an effect on the tumor progression and 
metastatic potential. The promoter variants were located in nucleotides evolutionarily 
conserved in higher mammals, which supports their functionality. None of the promoter 
variants located at the sites of known transcription factor binding sites on the PTEN promoter 
region (Figure 2), although effects on yet unidentified regulatory mechanisms cannot be 
excluded. 
The most likely function of a promoter variant would be regulatory effects on the gene. No 
difference in PTEN expression level was, however, detected between the tumors of variant 
carriers and non-carriers in expression microarray analysis, and it is possible that other 
somatic changes in tumors might have masked the effect. Very strong changes in the PTEN 
expression level would anyway be unlikely in the case of these variants, as effects that 
dramatic would lead to a PHTS phenotype, such as Cowden’s syndrome, in the variant 
carriers, which clearly was not the case here. Promoter mutations have indeed been shown to 
cause these diseases (Zhou et al. 2003). The variants detected here may affect the expression 
levels of PTEN on a smaller scale, consistently with the recent model of dosage-dependent 
tumor suppression of PTEN (Carracedo et al. 2011). Indeed, even a subtle decrease in the 
amount of the PTEN protein have been shown to increase cancer susceptibility in mice, to 
affect cellular proliferation in mouse mammary tissue, and affect the expression of 
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proliferation-related genes (Alimonti et al. 2010). As the promoter variants also lay on the 
5’UTR of the PTEN gene, it is possible that they may affect post-transcriptional regulation of 
protein synthesis, for example through mechanisms similar to those of eIF4F complex. Indeed 
some promoter mutations found in patients with Cowden’s syndrome affect the expression of 
the PTEN protein through dysfunctional translation instead of altered transcription by causing 
large mRNA secondary structure alterations (Teresi et al. 2007). 
The breast tumors of the patients carrying a PTEN promoter variant compared to matched 
tumors of non-carriers presented differential expression of 160 genes with patterns similar 
among -903GA, -975GC, and -1027GA carriers. The functional annotation linked the up-
regulated genes to entities of ATP or nucleoside binding and phosphorylation. Down-
regulated genes related to entities of DNA binding and transcriptional functions. The 
strongest down-regulation was seen in the BAMBI gene, a regulator of TGF-beta-family 
signaling (Onichtchouk et al. 1999). Increased expression of BAMBI has been detected in 
ovarian cancer (Pils et al. 2010) and it also predicts aggressive tumor phenotype and 
prognosis in colorectal cancer (Togo et al. 2008) as well as metastatic potential (Fritzmann et 
al. 2009). The expression of BAMBI is epigenetically silenced in high-grade bladder cancer 
(Khin et al. 2009). In mice the expression of BAMBI is limited to endothelial cells in which it 
acts as a regulator of angiogenesis (Guillot et al. 2012). The differentially expressed genes 
identified here, however, represent complex down-stream effects of PTEN promoter variants, 
and as they are measured in developed tumors, other regulatory abnormalities are likely 
present. Compared to the gene expression signature of somatic PTEN loss by Saal et al. (Saal 
et al. 2007) on the single gene level there was not much overlap. The somatic loss of gene 
expression of a major tumor suppressor happening at an advanced state of tumor development 
is, however, a different event from carrying a predisposing germline variant, affecting the 
tumorigenesis at an early state. The Saal signature genes annotated, nevertheless, to 
overlapping functional categories, as did the genes in the signature described here. 
When the 160 signature genes were used to divide the tumors of 183 patients by clustering 
analysis based on the overall expression into two groups, an association between the signature 
and patient survival was revealed. This association was confirmed in independent datasets, 
indicating that the signature has similar prognostic effects to PTEN promoter variants and 
highlights the biological importance of the signature genes. The prognostic effects of the 
promoter variants may be carried out through their downstream effects on the signature genes. 
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When the Saal signature was applied for survival analysis, the clustering of the tumors into 
two categories was highly correlated between the signatures, emphasizing their similarity and 
supporting the role the germline promoter variants play on PTEN-mediated tumor 
suppression. 
6.3 eIF4E 
Previous studies have established eIF4E as prognostic marker in breast cancer, but treatment 
stratified associations have not so far been investigated, nor survival of post-metastatic 
patients. One study had looked into the effects of eIF4E expression together with TLK1B 
(Tousled-like kinase 1B) in breast cancer in doxorubicine-treated patients with a significant 
effect on survival, but had no non-treated patient group available for comparison (Byrnes et 
al. 2007).  The study here, with 1,085 cases, is thus far the largest and most complete analysis 
of eIF4E in breast cancer. High expression of eIF4E was associated with characteristics of 
aggressive breast cancer and also with the triple negative subtype. Here, the most notable 
survival effect was seen in patients treated with anthracycline-based chemotherapy, 
suggesting that the patients with high levels of eIF4E in their tumors may have a 
compromised response to anthracycline. High expression of eIF4E also associated with 
survival in lymph node-positive and in metastasized breast cancer, suggesting that it has 
functions in these advanced forms of cancer and emphasizing the role of the protein as a 
prognostic biomarker with also a potentially predictive value. 
The overall picture of the cancer-related targets eIF4E regulates remains unclear (Hsieh, 
Ruggero 2010). Many such transcripts are known, for instance the MCL-1 (Wendel et al. 
2007) protein which has antiapoptotic properties, and when overexpressed, has been linked to 
high grade of breast cancer and worse prognosis (Ding et al. 2007). Another potential 
regulatory target of eIF4E is TLK1B, which links DNA damaging agents, such as 
anthracycline, to eIF4E over expression, as TLK1B functions in the repair of DNA double-
strand breaks caused by doxorubicine or radiation (Sunavala-Dossabhoy et al. 2004) and its 
over expression has been associated with radio resistance (Li et al. 2001). The translation of 
numerous transcripts is, however, regulated by eIF4E, and to reveal the mechanisms behind 
results described here, further functional investigations are required. There is also potential to 
apply eIF4E in cancer treatment by targeting it directly by using, for instance, synthetic 
nucleotide cap-analogs or antisense oligonucleotides (Malina et al. 2011, Graff et al. 2008, 
Hsieh, Ruggero 2010). 
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7 Summary and Conclusions 
Since the discovery of the PALB2 gene in 2006 and its initial identification as a breast cancer 
susceptibility and Fanconi anemia gene the following year, the gene has been under 
investigation by several research groups in various populations. The low frequency of 
mutations has, however, limited the characterization of the tumor phenotype and even more 
the association analysis of prognostic effects among the mutation carriers. The Finnish 
founder mutation 1592delT was present in 19 familial (2.0%) and 8 sporadic (0.6%) breast 
cancer patients and in 2 (0.2%) population controls. This confirmed the risk effect of the 
mutation and demonstrated a trend of increasing frequency of the mutation with increasing 
family history of breast cancer. The risk estimation of the PALB2 mutation will become more 
precise in the near future when the efforts of an international consortium with large enough 
sample sets for thorough analyses will be finalized. 
When the properties of 33 tumors of the mutation carriers were analyzed, they were 
associated with higher grade and expression of Ki67 proliferation marker and presented more 
frequently clinically challenging triple negative subtype. The PALB2 mutation was also 
associated with breast cancer survival, particularly in familial patients and in patients with 
HER2 negative tumors. These features were shared with the BRCA2 mutation carriers. The 
results here also indicate BRCA2 mutation as a prognostic factor, which together with other 
recent findings (Goodwin et al. 2012), supports preventive measures and extended and more 
careful follow-up of the patients with BRCA2 mutations. The genetic testing of PALB2 
mutations in breast cancer families in Finland might be beneficial for the risk assessment and 
screening of the healthy mutation carriers and also for the management of treatment and 
follow-up of the affected individuals. The relatively high frequency of the 1592delT mutation 
in Finland should make the genetic testing cost-efficient together with BRCA1 and BRCA2 
founder mutations. Further studies are, however, required also to identify other risk variants in 
the PALB2 carrier families, as the increase in risk caused by the mutation is unlikely to 
account for the entire cancer burden in these families. 
As a key regulator of activation of the PI3K/AKT pathway and as a major tumor suppressor, 
PTEN is one of the most thoroughly studied human genes. Three low-frequency promoter 
polymorphisms, -903GA, -975GC, and -1026CA, associated with worse survival of breast 
cancer patients and presented an expression signature of 160 genes in the tumors of variant 
carriers compared with matched non-carriers. The signature genes further stratified breast 
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cancer patients into distinct survival groups in independent datasets, supporting the effects of 
germline variants on gene expression signatures and on metastatic development in breast 
cancer. This suggests that the germline PTEN promoter variants affect metastatic potential 
and tumor progression in breast cancer and indicates that they are prognostic markers. To our 
knowledge these findings are the first clinically relevant associations of germline PTEN 
variants outside hamartomatous polyposis syndromes, although further studies are warranted 
to validate these findings. The results are in line with the dosage-dependent model of PTEN 
tumor suppression, according to which even very subtle reduction of the amount of the PTEN 
protein affects the tumor development. Associations of variants this rare would not have been 
detected in GWAS on breast cancer survival as they have been powered only to detect 
stronger effects of more common variants. 
Abnormal translation is one of the mechanisms frequently occurring during carcinogenesis. A 
major regulator of translation of many cancer-related transcripts is the eIF4F complex, which 
is regulated strongly by the amount of free eIF4E. The expression of eIF4E has previously 
been associated with prognosis of breast cancer, but the studies have been of very limited 
size. Here the expression of eIF4E was investigated by thus far the largest and most 
specifically characterized dataset, revealing associations with multiple characteristics of 
aggressive breast cancer and with the triple negative subtype. High expression of eIF4E also 
associated with the survival of breast cancer patients and, in subgroup analysis, a particularly 
strong effect was identified in patients treated with anthracycline-based chemotherapy. These 
results support eIF4E as a prognostic marker and emphasize the potential of therapies 
targeting this protein. 
The findings of this study emphasize the potential of germline variants in high and moderate-
penetrance susceptibility genes like BRCA2 and PALB2, as well as polymorphic variants like 
the PTEN promoter SNPs, as prognostic markers in breast cancer. The role of eIF4E as a 
biomarker for aggressive disease with also predictive value might in the future help the 
assessment of cancer treatments, particularly anthracycline-based treatment. The breast cancer 
patients with the changes described here might benefit from more rigorous follow-up and 
from more aggressive treatment. 
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